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Developmental monoamine signaling impacts adult affective and aggressive 
behaviors  
Qinghui Yu 
            Most neuropsychiatric disorders have developmental origins and an emerging 
model postulates that such developmental vulnerability is often restricted to sensitive 
periods. The concept of sensitive developmental periods for the indelible modulation of 
complex behaviors is similar to that described for sensory systems (e.g. visual cortex, 
ocular dominance plasticity), but effected behaviors, modulating factors, and underlying 
mechanisms are much less well understood. Furthering our knowledge of sensitive 
periods that determine the developmental trajectory of complex behaviors is a necessary 
step towards improving diagnosis, prevention and treatment approaches for 
neuropsychiatric disorders. To fulfill this mission, I here investigate how genetic and 
environmental risk factors act during sensitive periods of brain development to alter 
adult behavior and thereby confer vulnerability to neuropsychiatric disorders. 
            My thesis is divided into four chapters. Chapter I provides general background 
and significance information relevant to chapters II-IV.  
            Chapter II focuses on elucidating and comparing the consequences of 
developmental serotonin (5-HT) transporter (5-HTT) and monoamine oxidase A 
(MAOA) blockade. Pharmacologic MAOA or 5-HTT blockade in adulthood has 
antidepressant and anxiolytic efficacy. Yet, genetically conferred MAOA or 5-HTT 
hypo-activity is associated with altered aggression and increased anxiety/depression. 
Here I test the hypothesis that increased monoamine signaling during development 
causes these paradoxical aggressive and affective phenotypes. I find that pharmacologic 
MAOA blockade during early postnatal development (P2-P21) increases anxiety- and 
depression-like behavior in mice, mimicking the effect of P2-21 5-HTT inhibition. 
Moreover, MAOA or dopamine transporter (but not norepinephrine transporter) 
blockade during peri-adolescence (P22-P41) increases adult aggressive behavior. 5-HTT 
blockade from P2-P21 or P22-P41 reduces adult aggressive behavior. Altered aggression 
correlates positively with locomotor response to amphetamine challenge in adulthood 
and striatal dopamine and DOPAC content is increased while brainstem 5-HIAA content 
is decreased in high aggression. Taken together, these data suggest that genetic and 
pharmacologic factors impacting dopamine and serotonin signaling during sensitive 
developmental periods confer risk for aggressive and emotional dysfunction in humans. 
            Chapter III focuses on refining the 5-HT sensitive period affecting anxiety and 
depression-like behavior. Specifically, I hypothesized that the identified P2-21 period, 
which encompasses many developmental processes, contains a narrower critical period, 
affecting fewer developmental processes but having the same impact on adult behavior. 
This experiment serves two purposes: First, I seek to gain insight into the neural 
substrates and possible developmental processes underlying developmental programing 
of anxiety- and depression-like behaviors through 5-HT signaling. Second, I aim at 
providing translationally relevant data, informing clinical and epidemiological studies as 
to which developmental window might be sensitive to 5-HT altering factors in humans. 
This thesis research shows that postnatal fluoxetine (PN-FLX) treatment from P2-11 
leads to increased adult anxiety- and depressive-like behavior in mice, while PN-FLX 
treatment from P12-21 or P22-41 has no effect in adult anxiety- and depressive-like 
behavior. In addition, adult chronic FLX treatment could not rescue the behavioral 
phenotype produced by P2-11 5-HTT blockade. 
            Chapter IV focuses on the role of 5-HT2A receptor signaling in mediating the 
effect of P2-11 5-HTT blockade on adult behavior. Htr2a-/- mice display reduced 
conflict anxiety. Because 5-HT2A receptor antagonists do not reduce conflict anxiety in 
adulthood, I hypothesized that the behavioral htr2a-/- phenotype is at least partially of 
developmental origin, which would further indicate that increased 5-HT2A receptor 
signaling during development could increase conflict anxiety. To investigate this 
hypothesis, I analyzed the effect of P2-11 5-HTT blockade on anxiety and depression-
like behaviors in htr2a+/+, +/-, and -/- mice. Supporting my hypothesis, I find that 
absence of htr2a improved performance of PN-FLX treated mice in the novelty 
suppressed feeding task, by decreasing the latency to feed to control levels. Absence of 
htr2a, however, did not have ameliorative effects on PN-FLX phenotypes in the open 
field and shock escape tests. In summary, these data demonstrate that 5-HT2A receptor 
signaling mediates some but not all consequences of increased P2-11 5-HT signaling. 
            Taken together, in my thesis work I identified and characterized two sensitive 
developmental periods whereupon early-life perturbation of monoamine signaling alters 
adult behavior: an early postnatal (P2-P11) 5-HT-sensitive period that affects anxiety 
and depression-related behaviors and a later peri-adolescent (P22-P41) DA- and 5-HT-
sensitive period altering aggression and behavioral sensitivity amphetamine. These data 
give insight into the etiology of neuropsychiatric disorders and should ultimately help 
improving diagnosis, prevention and treatment approaches.
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Chapter I  General Introduction 
I.I Depression and anxiety 
I.I.I Clinical presentation and treatments 
            Depression is a chronic, recurring illness that is among the most prevalent 
psychiatric disorders worldwide. Recent studies estimate that one in six adults in the 
United States will succumb to depression or anxiety in their lifetime (Kessler et al., 2005), 
and it is the third leading contributor to the global disease financial burden (Collins et al., 
2011). Depression has been categorized into several classes including major depressive 
disorder (MDD), dysthymic disorder, and bipolar disprder. MDD is associated with 
negative mood, pessimism, hopelessness, a loss of interest in formally pleasurable 
activities (anhedonia), fatigue or loss of energy, significant weight loss or gain, changes 
in appetite, and sleep patterns (The Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition; DSM-IV-TR, 2000).  
            Anxiety is a natural adaptive consequence of stress that helps to cope with 
stressors. Anxiety disorders are maladaptive, dysfunctional, chronic and persistent, and 
can grow progressively worse if not treated (Lesch et al., 2003). Anxiety disorders 
include generalized anxiety disorder (GAD), social anxiety disorder (also known as social 
phobia), specific phobia, panic disorder with and without agoraphobia, obsessive-
compulsive disorder (OCD), posttraumatic stress disorder (PTSD), anxiety secondary to 
medical condition, acute stress disorder (ASD), and substance-induced anxiety disorder. 
Anxiety is associated with worry, fatigue, difficulty concentrating, irritability, muscle 
tension, and sleep disturbance (The Diagnostic and Statistical Manual of Mental 




rate of ~28% (Kessler et al., 2005). Depressive and anxiety disorders display high 
comorbidity rates, with at least 50–60% of individuals with depression reporting a 
lifetime history of one or more anxiety disorders (Kaufman and Charney, 2000).  
            There are many different treatments for depression such as psychotherapy, 
antidepressant medication, and electroconvulsive therapy (ECT). The first generation 
antidepressant drugs were the tricyclic antidepressants and the monoamine oxidase 
inhibitors. Tricyclic antidepressants act to inhibit serotonin or norepinephrine reuptake 
transporters, whereas monoamine oxidase inhibitors inhibit monoamine oxidase (a major 
catabolic enzyme for monoamine neurotransmitters). The discovery of the acute 
mechanisms of antidepressant drugs led to development of numerous second-generation 
medications including serotonin-selective reuptake inhibitors (SSRIs) and 
norepinephrine-selective reuptake inhibitors (NSRIs). The availability of clinically active 
antidepressants also made it possible to develop and validate a wide range of behavioral 
tests with which to study depression-like phenotypes in animal models (Nestler et al., 
2002). However, current medications have their limitations. Some patients respond well 
to the treatments, while others only show partial responses or complete non-response 
(Fava and Davidson, 1996; Rush et al., 2006). In addition, current antidepressant 
medications require weeks of drug administration before achieving therapeutic benefits. 
SSRIs are also used as the first line treatment for anxiety disorders. The overlapping 
disease symptoms and treatment efficacies suggest that depression and anxiety might 
result from common pathophyiological conditions. The mechanisms of treatment and 




and depression disorders as well as mechanisms of therapeutic treatments remains an 
unmet need. 
 
I.I.II Genetic and environmental factors on depression/anxiety 
             Epidemiological and genetic studies demonstrate that both genetic and 
environmental factors contribute to depression and anxiety disorders. The prime example 
for genetic risk is the common functional polymorphism in the promoter region of the 
human serotonin transporter gene (5-htt), the 5HTTLPR, which affects 5-htt transcription 
and has been associated with neuroticism, elevated trait anxiety, and increased 
vulnerability to affective disorders in many studies (Collier et al., 1996; Lesch et al., 
1996; Levinson, 2006). Environmental stressors such as stressful life events (job loss, 
marital problems, major health problems and loss of close personal relationships) and 
adverse childhood experiences have also been associated with increased risk for anxiety 
and depression (Bernet and Stein, 1999; Mundt et al., 2000; Caspi et al., 2002; Arnow, 
2004).  
            The notion that environmental factors interact with genetic predisposition to affect 
psychiatric disease outcome has found great support in recent years. In this specific form 
the diathesis-stress model, genetic factors influence the risk of major depression in part 
by influencing the susceptibility of individuals to the depressive effects of stressful life 
events (Kendler, 1995; Silberg et al., 2001; Kendler et al., 2005; Karg et al., 2011). A 
landmark study carried out by Caspi and colleagues demonstrated that low expressing 
variants of the 5-htt interact with either early life stress (childhood maltreatment) or adult 




and suicidal behavior in the study subjects (Caspi et al., 2003). Many but not all studies 
could confirm these early findings (Kaufman et al., 2004; Kendler et al., 2005; Willis-
Owen et al., 2005; Chipman et al., 2007; Scheid et al., 2007; Power et al., 2010; 
Fergusson et al., 2011a; Karg et al., 2011), leading to the general consensus that 
individuals carrying the low expressing “s” allele are more prone to depressive symptoms 
in response to stressful events during adulthood and childhood than individuals carrying 
the higher expressing “l” allele (Caspi et al., 2003; Kendler et al., 2005; Taylor et al., 
2006; Mandelli et al., 2007; Aguilera et al., 2009). In addition, polymorphysm/mutations 
in genes encoding 5-HT receptors or tryptophan hydroxylase-2 (tph2) enzyme critical for 
synthesis of serotonin have been shown to interact with environmental factors to 
predispose individuals to depression and anxiety disorders (Strobel et al., 2003; Waider et 
al., 2011). Collectively, these underscore gene by environment (G×E) interaction.  
 
I.I.III Neural circuitry of depression and anxiety 
            Neuroimaging studies of subjects diagnosed with major depression have 
identified abnormalities in multiple areas of the brain including the prefrontal cortex 
(PFC), the amygdala, the hippocampus, the amygdala, and parts of the striatum and 
thalamus as well as the functional connectivity within neural circuitry (Drevets, 2003; 
Hulvershorn et al., 2011). For instance, a comprehensive meta-analysis compiling 225 
individual studies on brain changes revealed decreased volumes of the hippocampus, 
thalamus, frontal lobe and orbitofrontal cortex in major depressive disorder (MDD) 
patients in comparison to healthy controls (Kempton et al., 2011).  In addition, resting 




amygdala, and CBF response to a negative emotional valence is abnormal between 
depressive groups and controls (Drevets, 2003). Relative to controls, individuals with 
depressive disorder show reduced rostral anterior cingulate cortex (rACC) volume or 
gray matter (Frodl et al., 2008; Leung et al., 2009; Mak et al., 2009; Abe et al., 2010). 
The reduced grey matter volume in the prefrontal cortex is also revealed in neuroimaging 
studies (Drevets et al., 1997). These alterations might underlie the emotional, behavioral 
and cognitive manifestations of major depression. For example, changes in orbital and 
medial PFC areas are hypothesized to cause abnormal emotional behavior and stress 
responses. The striatum (particularly the ventral striatum or the nucleus accumbens 
[NAc]) and amygdala, and related brain areas, are important in emotional memory and 
stress response and could as a result mediate the anhedonia, anxiety, and reduced 
motivation (Nestler et al., 2002; Tye et al., 2011). The hypothalamus has been postulated 
to play a role in neurovegetative symptoms of depression, such as changes in sleep, 
appetite, and energy (Nestler et al., 2002). The hippocampus is involved in the regulation 
of mood and in mediation of antidepressant response (Samuels and Hen, 2011). These 
different brain regions implicated in depression form a series of interacting circuits 
(Drevets, 2001; Liotti and Mayberg, 2001; Nestler et al., 2002). Since the regions 
implicated in depression and anxiety undergo rapid changes during postnatal 
development, developmental events could potentially affect the maturation of these 






I.II.I Description of aggression 
            Aggression is a complex social behavior evolved in the context of defending and 
obtaining resources. Traditionally, aggression has been defined as overt behavior that has 
the intention of inflicting physical damage on another individual and the potential for 
aggressive behavior exists whenever the interests of two or more individuals conflict 
(Nelson and Trainor, 2007). The most widely utilized classification of aggression is that 
of premeditated aggression versus reactive aggression. Premeditated aggression, also 
referred to as proactive aggression, represents a planned behavior that is not typically 
associated with frustration or response to immediate threat and is more goal-oriented and 
purpose-full (Siever, 2008). In contrast, reactive aggression is considered to be more 
impulsive and characterized by high levels of autonomic arousal and precipitation by 
provocation associated with negative emotions (Feilhauer et al., 2011). Premeditated 
aggression is associated with cognitive control while reactive aggression is associated 
with little cognitive processing (Blair, 2001; Feilhauer et al., 2011). Reactive aggression 
becomes pathological if the aggressive responses are exaggerated in relation to the 
emotional provocation that occurs. Human aggression as a trait is assessed using 
psychometric measures including inventories, questionnaires and scales. Aggression 
figures prominently as a positive symptom in many neuropsychiatric disorders (Steiner et 
al., 2003; Chaplin, 2006; Haller and Kruk, 2006). Attention-deficit hyperactivity disorder 
(ADHD), mood disorders, and in particular bipolar disorders/pediatric mania, 
schizophrenia, conduct disorder, and borderline personality disorders are most notably 




2003; Perroud et al., 2011; Soyka, 2011). Thus understanding the neurobiology of 
aggression holds therapeutic promise for a range of neuropsychiatric diseases. 
 
I.II.II Genetic and environmental factors on aggression 
             Both genetic and environmental factors contribute to aggression and violence. 
Twin and adoption studies have suggested the presence of substantial genetic influence 
on aggression, especially impulsive aggression (Coccaro et al., 1993; Coccaro et al., 
1997; Miles and Carey, 1997). Genetic factors such as susceptibility genes contribute 
vulnerability towards the acquisition of abnormal aggressive behaviors. One prominent 
example of a single genetic factor contributing risk to aggression is a loss of function 
mutation in the monoamine oxidase A gene (maoa). This maoa null allele has been 
linked to male antisocial behavior and borderline mental retardation, as affected 
individuals display mild mental retardation, an increase in aggressive outbursts, anger, 
and fear, and violent impulsive behavior (e.g. rape, assault, arson, and exhibitionism) 
(Brunner et al., 1993b; Brunner, 1996). A low-expressing polymorphism, the maoa-
VNTR, is also associated with aggressive behavior (Manuck et al., 2000; Zalsman et al., 
2005; Jabbi et al., 2007). Other genes have also been associated with aggressiveness. The 
human polymorphism of low catechol-O-methyltransferase (COMT) activity points to the 
risk for increased aggressive behavior preferentially in males (Strous et al., 1997; 
Volavka et al., 2004). Furthermore, the tryptophan hydroxylase 1 (tph1) A779C 
polymorphism, which affects serotonin biosynthesis and influences 5-
hydroxyindoleacetic acid concentrations (5HIAA) in cerebrospinal fluid (CSF), may 




            Environmental factors such as stress, childhood maltreatment, and even 
socioeconomic factors also interact with different genetic variants to predispose to 
aggression (Kim-Cohen et al., 2005; Moffitt, 2005; Craig, 2007). A landmark study 
carried out by Caspi et al. showed that the maoa polymorphism interacts with childhood 
maltreatment and adversity to predispose to violence (Caspi et al., 2002; Kim-Cohen et 
al., 2006). Later many but not all studies replicated these findings showing that there is a 
positive interaction between maoa low expression alleles and childhood adversity for 
abnormal behavior including adult anti-social behavior (Foley et al., 2004; Haberstick et 
al., 2005; Huizinga et al., 2006; Kim-Cohen et al., 2006; Young et al., 2006; Prichard et 
al., 2008; Fergusson et al., 2011b; Philibert et al., 2011). In summary, human aggressive 
behavior is complex and multi dimensional, and genetic factors and lifetime experiences 
interact with each other to confer risk for pathological aggression. To adequately 
diagnose, treat, and/or prevent pathological aggression, one needs to understand the 
underlying pathophysiology, and the following chapters will summarize the current 
knowledge about the involvement of monoamine neurotransmitters and insight into the 
underlying circuitry. Another important and central factor for understanding how genetic 
and environmental factors confer risk is timing. In my thesis, I explored the hypothesis 
that the early life disruption of monoamine signaling would lead to altered adult 
behaviors. Understanding of the relationship between genetic factors that predispose an 
individual to display aggressive behaviors, life experiences, and timing promises a better 





I.II.III Monoamine and aggression 
Abnormal monoamine signaling has been implicated in aggression. The most prominent 
monoamine neurotransmitter alterations in aggression have been identified for 5-HT, 
norepinephrine, and dopamine. 
 
5-HT.  
            5-HT can affect aggressiveness and impulsivity. In general, low activity of the 5-
HT system has been associated with impulsive aggression in both human and animal 
studies (Coccaro et al., 1989; Linnoila and Virkkunen, 1992; Miczek et al., 1994). In 
humans, a low concentration of the 5-HT metabolite (5-HIAA) is associated with 
impulsivity and aggression (Brown et al., 1979; Virkkunen et al., 1994). In animal studies, 
low levels of 5-HIAA are linked to heightened impulsive and aggressive behaviors 
(Fairbanks et al., 2001). Manipulations that lower 5-HT signaling such as p-
chlorophenylalanine (PCPA) injection increase impulsivity and aggression; increasing 
serotonin activity with serotonin precursors or SSRIs can reduce aggression behavior in 
rodents (Chiavegatto et al., 2001; Miczek et al., 2001).  
            In terms of a role for 5-HT receptors in mediating aggressive behaviors, the anti-
aggressive effects of drugs activating 5-HT1A and 5-HT1B receptors have been extensively 
documented (Miczek et al., 1989; Sijbesma et al., 1991; Centenaro et al., 2008). 5-HT1A 
receptor agonists decrease several types of aggressivity (Olivier et al., 1995). Male mice 
that lack 5-HT1B receptors (htr1b-/-) are more aggressive than wild type mice, suggesting 
that 5-HT1B receptor signaling exerts inhibitory control on aggressive behavior (Saudou 




aggressive behavior and brain serotonin dysfunction (Chiavegatto et al., 2001). 5-
HTergic neurons in mice lacking the ETS transcription factor Pet1 are depleted by 80%, 
and this hypo-5-HTergic mouse model exhibits increased aggression in the resident-
intruder test (Hendricks et al., 2003).  In addition, mice lacking 5-HTT exhibited reduced 
aggressive behavior, which could be linked to the fact that 5-HTT deficient mice show 
significant reduction in tissue content of 5-HT measured in multiple brain regions 
(brainstem, frontal cortex, hippocampus, hypothalamus and striatum) (Bengel et al., 
1998; Holmes et al., 2002a; Mathews et al., 2004; Kim et al., 2005). In addition, social 
approach behavior is strongly reduced in 5-htt -/- mice as demonstrated by reduced time 
spent in a compartment containing a stimulus mouse (Page et al., 2009). Taken together, 
these various studies support the notion that aggression is associated with serotonin 
dysfunction and changes in the metabolism of serotonin could predict aggressiveness. 
Traditionally, studies in humans and animals indicate that 5-HT activity (such as CSF 5-
HIAA) is inversely related to certain kinds of aggression such as hostile aggressive 
behavior. 
 
Dopamine (DA).  
            The DAergic system is involved in behavioral activation, motivation, and reward 
processing (Ikemoto and Panksepp, 1999; Everitt and Robbins, 2000; Volkow et al., 
2011). It also plays an active role in the modulation of aggressive behaviors.  The D2-
receptor antagonist haloperidol is used effectively to treat aggressive patients who are 
also psychotic (de Almeida et al., 2005). In animal studies, hyperactivity in the dopamine 




Soderstrom et al., 2001). Systematic administration of the DA agonists methamphetamine 
or apomorphine decreased the threshold for defensive attack behavior elicited by 
electrical stimulation of the ventromedial hypothalamic nucleus (Maeda et al., 1985; 
Maeda and Maki, 1986). Increased accumbal DA release was observed in anticipation of 
the aggressive episodes in rats (Ferrari et al., 2003) as well as during and following 
aggressive encounters (Tidey and Miczek, 1996; van Erp and Miczek, 2000). These 
neurochemical studies link elevated DA and its metabolites in the prefrontal cortex and 
nucleus accumbens not only to the initiation of attacks and threats, but also to the 
defensive and submissive responses in reaction to being attacked (Puglisi-Allegra et al., 
1990; Tidey and Miczek, 1996). Blockade of dopamine D1 or D2 receptors in the nuclear 
accumbens attenuate aggressiveness in mice (Couppis and Kennedy, 2008).  
            Genetic studies have been done to characterize the molecular aspects of dopamine 
function in aggression.  Disruption of the DAT increases extracellular dopamine 
concentrations in the striatum causing hyperdopamine tone, and DAT knockout mice 
show increased reactivity and aggression in some behavioral tests (Rodriguiz et al., 2004). 
Heterozygous COMT-deficient male mice exhibited increased aggressive behavior and 
increased frontal cortex dopamine levels (Gogos et al., 1998). In summary, studies 
focused on elucidating the association of DA activity in appropriate expression of 
aggressive behavior. In general, aggressiveness is associated with hyper-DA activity. 
 
Norepinenephrine(NE) 
            Desipramine , which is a NE transporter inhibitor, dose-dependently increases the 




DSP-4, a selective NE neurotoxin, significantly attenuates the enhancing effect of 
desipramine on aggressive behavior (Matsumoto et al., 1991; Matsumoto et al., 1995; 
Haller et al., 1998). In addition, mice that lack α2C-adrenergic autoreceptors consequently 
have increased NE levels and show enhanced isolation-induced aggression toward an 
unfamiliar intruder, whereas mice that over-express these receptors show the opposite 
effects (Sallinen et al., 1998). Dopamine beta-hydroxylase knockout (Dbh -/-) mice 
lacking NE do not exhibit aggression in resident-intruder test (Marino et al., 2005). Taken 
together these findings demonstrate that NE signaling is positively correlated with 
aggressiveness. Mice lacking MAOA are hyper-aggressive and show significantly 
elevated levels of NE and 5-HT in hippocampus, the frontal cortex, striatum and the 
cerebellum as well as elevated levels of DA in striatum, which indicates that abnormal 
NE levels might be casually involved in the aggressive phenotype of these mice (Kim et 
al., 1997; Chen et al., 2007).  
 
            In summary, the NE, 5-HT and DA systems show substantial changes associated 
with aggressive phenotype. Perturbations in monoamine systems might produce profound 
changes in circuitry, structure and function of the brain, which contribute to the abnormal 
aggressive behaviors. However, the detailed manner in which different monoamine 
systems regulate aggressive behaviors is not clear. A lot of questions remain unanswered. 
For example, to which extent do monoamines and their metabolite level reflect an 
aggressive trait? Can transient perturbations produce aggressive states/traits? Can 
different monoamines interact with each other to potentiate aggressive behaviors? 






I.II.IV The neural circuitry of aggression 
            There are structural and functional brain changes implicated in aggressiveness. In 
humans, reductions in prefrontal gray matter have been reported in individuals with 
antisocial personality disorders (Raine et al., 2000). Healthy subjects demonstrated blood 
flow reductions in the orbital frontal cortex in an unrestrained aggressive scenario in 
imaging studies (Pietrini et al., 2000). Patients with a history of violent behaviors 
displayed significantly decreased prefrontal activity compared to non-aggressive patient 
controls (Amen et al., 1996). Positron emission tomography (PET) studies in subjects 
with impulsive personality disorders or psychiatric patients with a history of violence 
show relative hypo-metabolism compared with healthy control subjects in areas of frontal 
and temporal cortex (Goyer et al., 1994; Volkow et al., 1995; Soloff et al., 2003). Patients 
with orbital and medial prefrontal cortex lesions exhibit impulsive and aggressive 
behavior (Davidson et al., 2000). In rodents, lesions of the orbitofrontal cortex increase 
aggression in rats (de Bruin et al., 1983). Since prefrontal cortex modulates subcortical 
circuitry to influence emotional response, it is postulated that impaired regulatory control 
of the prefrontal cortex may lead to excessive negative emotional reactivity and 
consequent violent behaviors.  
            The amygdala, hypothalamus and hippocampus have also been implicated in 
aggression. Borderline personality disorder patients exhibit increased activation of the 
amygdala in response to negative pictures versus a resting condition (Minzenberg et al., 




reduced left hippocampal activity and greater right activity has been reported in anti-
social subjects (Raine et al., 1997; Raine et al., 2004). Hypothalamic activation has also 
been associated with aggression in domestic violence perpetrators (George et al., 2004). 
Animal studies have also been conducted to investigate the brain regions involved in 
aggression.  Experiments in cats have shown that attack behavior can be elicited by 
electrical stimulation of the hypothalamus (Siegel et al., 1999). Chemical (cholinergic) 
stimulation of the septum elicits rage behavior in the cat (Siegel and Skog, 1970). 
Amygdala lesions attenuated the facilitatory influences produced by the provocation on 
thresholds for hypothalamic defensive attack (Maeda and Maki, 1986). In rats, electric 
stimulation of the hypothalamus also induces aggression (Kruk et al., 1984). Recent 
technical innovation has advanced the understanding of circuitry of aggression. 
Optogenetic stimulation of neurons in the ventrolateral subdivision of the ventromedial 
hypothalamus (VMHvl) causes male mice to initiate attacks and pharmacogenetic 
silencing of the VMHvl reversibly inhibits inter-male aggression (Lin et al.). Taken 
together, an imbalance between limbic “drives” and prefrontal control mechanisms might 
be very important for the regulation of aggression episodes. However, research towards 
the circuitry underlying aggression is still very sporadic and primitive, which presents an 
unmet need to elucidate the changes in brain structure and circuitry underlying different 





I.III The 5-HT and the DA system in the brain 
 
I.III.I 5-HT function and signaling  
            5-HT regulates a variety of physiological functions, including thermoregulation, 
respiration, circadian rhythm, sleep, appetite, aggression, sexual behavior, pain 
modulation, neuroendocrine modulation, and cognition (Halford et al., 2005; Popova, 
2008; Hilaire et al., 2010; Ravindran and Stein, 2010; Bardin, 2011; Monti, 2011). It is 
involved in a variety of pathological conditions such as depression, anxiety (general 
anxiety disorder, obsessive compulsive disorder, social phobia), schizophrenia, and 
impulsive disorders (Lucki, 1998; Stahl, 1998).  
            5-HT is synthesized from the amino acid tryptophan through the action of two 
enzymes: tryptophan hydroxylase (TPH) and amino acid decarboxylase (DDC). The first 
step in the synthesis of 5-HT is the TPH-mediated reaction converting tryptophan to 5-
Hydroxy-L-tryptophan (5-HTP). This is the rate-limiting step in the pathway. In the 
second step, 5-HTP is converted to serotonin by the DDC (Walther et al., 2003). The 
vesicular monoamine transporter type 2 (VMAT2) then transports 5-HT from the 
neuronal cytoplasm into vesicles (Takahashi et al., 1997). 5-HT is released into the 
synaptic cleft in an activity-dependent manner. Once serotonin is removed from synaptic 
terminals via 5-HTT, it is repackaged into vesicles or degraded by monoamine oxidase A 
to be converted into 5-HIAA (Sangkuhl et al., 2009).  
5-HT signals through at least 14 receptors in the central nervous system. 5-HT 
receptors are seven putative transmembrane spanning G-protein coupled metabotropic 
receptors, except for one member of the family, the 5-HT3 receptor, which is a ligand-




HT1–7) on the basis of their structural, functional and to some extent pharmacological 
characteristics. In the intact brain the function of many 5-HT receptors can be 
unequivocally associated with specific physiological responses, ranging from modulation 
of neuronal activity and neurotransmitter release to behavioral changes (Berg et al., 1998; 
Barnes and Sharp, 1999).  
.  
I.III.II DA function and signaling 
 DA has long been know to important in emotional regulation, reward, motivation 
and cognitive processes (Bromberg-Martin et al., 2010; Koob and Volkow, 2010; Cools 
and D'Esposito, 2011). The DA system has also been implicated in a variety of 
neuropsychiatric disorders such as Parkinson’s disease, depression, anxiety, 
schizophrenia, ADHD and addictive disorders (Drevets, 2001; Wise, 2002; Ross and 
Peselow, 2009; Heinz and Schlagenhauf, 2010; Koob and Volkow, 2010). The DAT 
regulates presynaptic dopamine homeostasis, and controls the activity of released 
dopamine by rapid uptake into presynaptic terminals (Giros and Caron, 1993; Jones et al., 
1998). The DAT is the main target for psychoactive drugs, such as amphetamine and 
methylphenidate. Pharmacological agents that block the DAT display efficacy in treating 
attention dysfunction, hyperactivity, and impulsivity of ADHD.  
The amino acids phenylalanine and tyrosine are precursors for catecholamines 
(dopamine, norepinephrine and epinephrine). The sequence of enzymatic steps starts with 
the enzyme tyrosine hydroxylase (TH), which converts the amino acid L-tyrosine into 
3,4-dihydroxyphenilalanine (L-DOPA). L-DOPA is then converted into DA. The 




Vesicular Monoamine Transporter (VMAT-2) then takes up dopamine into the storage 
vesicles. The vesicles release their content through Ca-activated fusion with the neuronal 
membrane. Afterwards, the action of DA released at the synapse is terminated by 
diffusion or reuptake into presynaptic nerve terminals by the DAT (Jones et al., 1998; 
Viggiano et al., 2003). 
 
I.IV Monoamine Oxidase and Serotonin Transporter   
In the following paragraphs, I will introduce the fundamental properties of the genes 
coding for the MAOA and 5-HTT, which will shed light in understanding the relationship 
between these genes and their functions during development as well as in adulthood.  
 
I.IV.I. General description of MAO and 5-HTT 
  MAOs catalyze the oxidative deamination of a number of biogenic amines in the 
brain and peripheral tissues (Shih, 1991). MAOs maintain low cytosolic and extra-
cellular levels of monoamines and prevent various natural substrates from accumulating 
in monoaminergic neurons as false neurotransmitters. On the basis of substrate selectivity 
and inhibitor sensitivity, two forms of MAO were proposed and designated MAOA and 
MAOB. MAOA mainly metabolizes monoaminergic neurotransmitters, such as 5-HT, 
dopamine (DA), NE, and epinephrine (E), whereas MAOB mainly metabolize trace 
amines, such as tyramine and phenylethylamine (Strolin Benedetti et al., 1992). Both 
MAOA and MAOB are located throughout the brain in the outer membrane of 
mitochondria (Green and Youdim, 1975) and are encoded by different genes (Grimsby et 




            In humans, 5-htt gene is located on chromosome 17q11.2 and is composed of 14 
exons (Ramamoorthy et al., 1993). The 5-HT system is involved in the pathology of 
depression and the action of antidepressants. The main regulator of 5-HTergic 
neurotransmission is 5-HTT. It transports 5-HT from synaptic cleft into presynaptic 
neurons, effectively regulating 5-HTergic tone (Gorman and Kent, 1999a). 5-HTT is 
situated both in perisynaptic membranes of nerve terminals and in dendritic arbors in 
close proximity to 5-HT-containing cell bodies in the midbrain and brain stem raphe 
nuclei. 5-HTT mediates rapid removal and recycling of released serotonin following 
neuronal stimulation (Murphy et al., 2004a). The 5-HTT is the primary molecular target 
for many antidepressants, especially the serotonin selective reuptake inhibitors (SSRIs). 
SSRIs are used as the first-line treatment for psychiatric conditions such as major 
depression, generalized anxiety disorder, panic disorder, and obsessive compulsive 
disorder (Gorman and Kent, 1999b). SSRIs increase 5-HTergic tone, and this 
biochemical effect is thought to be the basis of their therapeutic actions. 
 
Figure 1-1. 5-HTT and MAOA. 5-HTT transports 5-HT from synaptic cleft into 
presynaptic neurons, effectively regulating 5-HTergic tone. MAOA is located in the outer 
membrane of mitochondria, and mainly metabolizes monoaminergic neurotransmitters, 
such as 5-HT, DA, NE, and E. [based on (Green and Youdim, 1975; Strolin Benedetti et 





I.IV.II. MAOA and MAOB expression 
            In humans and rodents, MAOA is present before MAOB in most tissues. MAOA 
is almost at adult levels at birth, whereas MAOB activity increases several-fold with 
aging (Saura et al., 1994a, b). Both maoa and maob are co-expressed in 5-HTergic 
neurons of the raphe from E12 to P7. During postnatal life, maoa expression declines, 
whereas maob expression remains stable. maoa is expressed in the noradrenergic and 
adrenergic neurons during embryonic and postnatal development. maoa is expressed in 
several dopaminergic cell groups including ventral tegmental area, substantia nigra, 
ventral thalamus, hypothylamas, paraventricular nucleus during embryonic or postnatal 
development. maob is expressed in the histaminergic and forebrain cholinergic cell 
groups. (Vitalis et al., 2002) 
            In adulthood, the distribution of MAOA and MAOB differs as well (Levitt et al., 
1982; Saura et al., 1992; Jahng et al., 1997). maoa expression analysis in the rat using in 
situ hybridization shows that maoa has wide expression in the brain: maoa mRNA is 
localized in major monoaminergic cell groups such as locus ceruleus, the raphe nuclei, 
the substantia nigra and the ventral tegmental area; maoa mRNA is also found in 
forebrain structures such as the cortex, the hippocampus, the thalamus, and the 
hypothalamus (Jahng et al., 1997). In contrast to maoa expression, maob mRNA is 
expressed intensively in only three brain areas: the area postrema, the dorsal raphe, and 
the subfornical organ (Jahng et al., 1997). Immunohistochemical studies also showed that 
MAOB immunoreactivity is positive in two areas of the CNS: cells in the brain stem 
raphe and scattered cells in the hypothalamus (Levitt et al., 1982). Quantitative enzyme 




paraventricular thalamus, bed nucleus of the stria terminalis, median habenular nucleus, 
ventromedial hypothalamus, raphe nuclei, solitary tract nucleus, inferior olives, 
interpeduncular nucleus, claustrum. In contrast, MAOB is most abundant in the 
ependyma, circumventricular organs, olfactory nerve layer, periventricular hypothalamus, 
cingulum, hippocampal formation, raphe nuclei, paraventricular thalamus, mammillary 
nuclei, and cerebellar Bergmann glia cells (Saura et al., 1992). The different expression 
patterns of maoa and maob suggest that they exert different physiological functions.  
 
I.IV.III. 5-HTT expression 
            5-htt becomes transcriptionally active at embryonic day 10 (Moiseiwitsch and 
Lauder, 1995). In situ hybridization and immunochemistry study showed that 5-htt is 
expressed in 5-HTergic and non-5-HTergic cell groups from E13 in mice and E13.5 in 
rats (Lebrand et al., 1998). 5-htt is expressed in the mouse forebrain by E15. 5-htt is 
expressed in hippocampus, in dorsal subiculum, in endopiriform nuclei, and in cingulated, 
prelimbic, infralimbic, and retrospenial cortices (Lebrand et al., 1998). 5-HTT 
immunoreactivity is found in fiber tracts arising from the nuclei (Lebrand et al., 1998). 
The highest 5-htt expression is present between P0-P7 in most regions such as cortex, 
hippocampus, and subiculum (Lebrand et al., 1998).  
            5-htt and maoa expression are present in brain regions implicated in 
anxiety/depression and aggressive behaviors and are evolving dynamically during the 
early postnatal period. Both 5-HTT and MAOA are important in keeping metabolic 




potentially change the dynamics of the monoamine system and lead to profound effects 
later in adulthood. 
 
I.V Developmental hypothesis of neuropsychiatric diseases 
 
 I.V.I. The sensitive period during development 
            The concept of critical period has been clearly demonstrated in the development 
of visual system. Torsten Wiesel and David Hubel, who were awarded Nobel Prize for 
their significant contribution in visual information processing, made the first detailed 
observation. They showed that if you deprive one eye of a kitten during early life and let 
it mature to adulthood, there is a dramatic change in the Ocular Dominance (OD) 
distribution among the neurons in the visual cortex, while the same manipulation in adult 
cat dose not produce similar effects (Hubel and Wiesel, 1970). Further detailed 
characterization of the sensitive period demonstrated that four to six weeks after birth is 
the peak for this kind of OD distribution shift and it gradually declined until 6 months of 
age (Cynader et al., 1980). Similar phenomenon has also been shown in mice studies. The 
OD shift occurred during a critical period between P19 to P32 and the peak occurred 
between P28 to P32 (Gordon and Stryker, 1996). This OD plastic phenomenon is 
restricted to a critical period during development. Here the critical period refers to a strict 
time window during which experience provides information that is essential for normal 
development and permanently alters performance, which is a stricter definition than 
sensitive period (a limited time during development, during which the effect of 
experience on brain function is particularly strong) (Hensch, 2005a). Maturation of the 




(Hensch, 2005a, b). During this critical period in early life, neural circuitry or structure is 
sculpted by visual experience, which in turn results in changes in adult behavior. Multiple 
approaches have shown effective for recovery of function in adulthood, including 
environmental enrichment chronic administration of FLX, 10-day dark exposure (He et 
al., 2007; Sale et al., 2007; Maya Vetencourt et al., 2008). In particular, chronic FLX 
treatment could restore the visual plasticity caused by early occlusion of one eye. This is 
accompanied by reduced inhibition and increased Brain-Derived Neurotrophic Factor 
(BDNF) expression (Maya Vetencourt et al., 2008). This OD shift phenomenon provides 
a model for further understanding how early life experience shapes the brain development 
and result in different adult behaviors; in addition, it also carries further impact in 
understanding developmental disorders. 
 
Figure 1-2. Occlusion of one eye during early development produces loss of response to 
the deprived eye. The OD of cells is rated on a seven-point scale of neuronal 
responsiveness. After 3 or more days of monocular deprivation, the distribution shifted to 
the open eye. [from (Hensch, 2005a)] 
 
            Neuropsychiatric disorders also have developmental origins and such 
developmental vulnerability is often restricted to sensitive periods. Early life blockade of 
5-HTT from P4-P21 produced increased anxiety and depression like behaviors (Ansorge 




exposure, demonstrating that 5-HT effects on adult behavior are developmentally specific 
(Ansorge et al., 2008). Postnatal pharmacological blockade of 5-HT1A receptor from P13-
P34 produced increased anxiety/depression like behaviors (Lo Iacono and Gross, 2008), 
and 5-HT1A receptor expression in early development is required to establish the normal 
adult anxiety phenotype (Gross et al., 2002). The 5-HT1A receptor have two distinct 
populations in the brain (autoreceptors and heteroreceptors) that could each impact the 
distinct circuitry underlying mood and anxiety in development or adulthood. Suppression 
of 5-HT1A autoreceptors throughout life is sufficient to increase anxiety in the adult, 
while suppression of the heteroreceptors beginning either in early postnatal period or in 
adulthood is not sufficient to impact anxiety-like behavior, suggesting 5-HT1A forebrain 
heteroreceptors are not the primary mediators on developing anxiety circuitry and 
autoreceptor mediated events might be responsible for this normal establishment of 
anxiety behaviors (Richardson-Jones et al., 2011). Risk factors that impact monoamine 
signaling during a sensitive period might alter brain maturation and circuitry formation, 
which influence vulnerability of neuropsychiatric disorders. Thus, it is very important to 
further elucidate the sensitive periods that determine the developmental trajectory of 
complex behaviors to improve preventive and therapeutic approaches towards 
neuropsychiatric disorders. 
 
I.V.I. 5-HT system during development  
            The 5-HTergic system is among the earliest bioamine systems to appear during 
brain development. In the human, 5-HT neurons can be detected when the embryo is 5 




10th week of gestation (Levallois et al., 1997). After 15 weeks of gestation, clustering of 
the 5-HT cell bodies in the raphe nuclei is observed (Takahashi et al., 1986). Levels of 5-
HT increase during the first 2 years after birth and then decline to adult levels after the 
age of five (Sodhi and Sanders-Bush, 2004). In rodents, the first 5-HT neurons appear at 
the 11th day of rodent gestation. They continue to elaborate and innervate target structures 
throughout the early life of the organisms, finally reaching a mature status (Lauder, 1990). 
Although 5-HT axons reach target areas by birth, innervation and arborization is highly 
dynamic until postnatal day (P21) (Whitaker-Azmitia, 2005). During the first two 
postnatal weeks, rodent primary sensory cortex (notably layer IV of visual, auditory, and 
somatosensory areas) is transiently innervated by aggregates of 5-HT-containing neurons 
(D'Amato et al., 1987; Blue et al., 1991). In addition, several non-serotonergic neurons 
transiently express a serotonergic phenotype during early brain maturation in rodents 
(Cases et al., 1996; Lebrand et al., 1998; Salichon et al., 2001; Gaspar et al., 2003).  
            Electrophysiological studies have demonstrated differential effects of 5-HT on 
prefrontal cortex neurons during early and late development (Beique et al., 2004b; Beique 
et al., 2004a). For instance, in rat layer V pyramidal neurons serotonin induced excitatory 
response between P6 and P14 and inhibitory responses after P20. This effect has been 
attributed to a shift in 5-HT receptors, with 5HT2A receptor mediating the depolarization 






I.V.II. DA system during development 
            Midbrain DA neurons appear between embryonic days E12–15. These neurons 
begin to express tyrosine hydroxylase by E12.5, and then extensively migrate from the 
rhombic isthmus in a rostro-ventral direction to the ventral midbrain (Viggiano et al., 
2003). Starting from E15 the first DA-positive fibers pass through the developing 
striatum to cortical regions. The development of the cortical DA innervation continues 
until P60. No difference in density and topography was observed between postnatal days 
60 and 90 (Kalsbeek et al., 1988). In addition, DA transporter density in the striatum 
increases from postnatal day 25 through postnatal day 50, and then decreases 
continuously until P90 (Moll et al., 2000). During adolescence, the DA system has 
evident changes such as increased prefrontal cortex fiber density (Kalsbeek et al., 1988) 
and pruning of DA receptors (Teicher et al., 1995; Tarazi et al., 1998a, b).  
 
I.V.III. Monoamine functions as trophic factors during development  
            During embryonic and postnatal development, monoamines act as trophic factors 
modulating neurodevelopmental processes, such as cell division, migration, and 
differentiation, axonal and dendritic elaboration and connectivity, myelination and 
apoptosis (Haydon et al., 1984, 1987; Lauder, 1990; Teicher et al., 1995; Tarazi et al., 
1998b; Gaspar et al., 2003; Popolo et al., 2004; McCarthy et al., 2007). For example, 
studies on barrel field formation also provide insight into the role of developmental 
monoamine signaling on adult behavior. maoa and 5-htt -/- mice exhibit disrupted barrel 
fields  (Cases et al., 1996; Salichon et al., 2001). Barrels fields are the morphological 




afferents from one whisker through specific thalamic afferents, which normally form 
discrete clusters in cortical layer IV (Cases et al., 1996; Salichon et al., 2001). Increased 
5-HT signaling through 5-HT1B receptors on thalamocortical neurons during late-
embryonic/early-postnatal development has been shown to be causal for this phenomenon 
(Cases et al., 1996; Vitalis et al., 1998; Salichon et al., 2001; Rebsam et al., 2002). These 
findings demonstrate that high levels of serotonin during a critical perinatal period cause 
permanent anatomical defects. The mechanism elucidated in these studies suggested that 
thalamocortical neurons transiently adapt a 5-HTergic phenotype during the critical 
perinatal period, and that enhanced 5-HTergic signaling disrupts axonal arborization and 
patterning of the thalamocortical neurons projecting to the somatosensory cortex, which 
in turn defines the overall barrel field pattern. 5-HT is also critical for growth cone 
elongation (Haydon et al., 1984, 1987) and plays a role in the formation of the dorsal and 
median raphé nuclei (Rumajogee et al., 2004). 5-HT influences the length of dendrites, 
the formation of the dendritic spines, and branches in the hippocampus and cortex (Mazer 
et al., 1997; Yan et al., 1997; Wilson et al., 1998; Norrholm and Ouimet, 2000). 5-HT 
influences synaptogenesis. 5-HT depletion significantly slows the progress of 
synaptogenesis (Wilson et al., 1998; Faber and Haring, 1999). Taken together, these data 
demonstrate the central role that 5-HT plays during development to modulate specific 
processes that impact brain maturation and structure long-lastingly.  
            DA regulates cell proliferation, differentiation and neuronal pruning (Tarazi et al., 
1998b, a; Popolo et al., 2004; McCarthy et al., 2007). In addition, the developmental 
effects of monoamines may be linked to the transient expression of some molecules that 




enzyme in the catecholamine synthetic pathway, is transiently present in a subpopulation 
of cortical interneurons in the developing cortex of rodents (Berger et al., 1985). The 5-
HTT and the VMAT2 are present in non-monoaminergic neurons of the sensory thalamus 
and in selected neurons of the cerebral cortex of rats and mice (D'Amato et al., 1987; 
Lebrand et al., 1996; Lebrand et al., 1998).  
 
Figure 1-3. Serotonin acts as trophic factors during development impacting brain 
maturation. [based on (Gaspar et al., 2003; Innocenti and Price, 2005; Lenroot and Giedd, 
2006)] 
 
I.V.IV Brain structures and functions during development 
            Brain structures and circuitry modulating adult psychiatric behaviors are 
developing and maturing during early development. For example, cortical development 
and the establishment of cortical-cortical and cortical-subcortical networks take place in 
the first few postnatal weeks (Innocenti and Price, 2005; Dupont et al., 2006; Brockmann 
et al., 2011; Janiesch et al., 2011). Likewise, in rodent hippocampal development takes 
place during the early post-natal period, coinciding with the time that serotonergic 
neuronal innervation matures (Swann et al., 1989; Tansey et al., 2002; Gaspar et al., 
2003). Glutamatergic neurons undergo rapid development postnatally, changing spine 
density and synapse characteristics (Hoftman and Lewis, 2011). Gamma-aminobutyric 
acid (GABA) neurotransmission is rapidly evolving during postnatal development, 




and Anderson, 2006). A critical developmental period for the neocortex in rodents occurs 
during the first 2 postnatal weeks, which is also a period of intense synaptogenesis, as 
synaptic density increases fivefold between P10 and P15 when it is almost at the level of 
adult brain (Micheva and Beaulieu, 1996). Thus, interference with monoamine signaling 
during early development conceivably impacts developmental trajectory of neuronal 
circuitry and brain maturation, which may ultimately lead to altered adult behavior. 
 
I.V.V. Paradox of 5-HTT genetic life-long inhibition vs pharmacological blockade  
            Mice constitutively lacking the 5-HTT exhibit increased anxiety/depression like 
behaviors (Holmes et al., 2003; Lira et al., 2003). In humans, people with low-expression 
allele of 5-htt gene are more likely to develop depressive episodes in face of stressful life 
events (Caspi et al., 2003; Kendler et al., 2005; Taylor et al., 2006; Cervilla et al., 2007; 
Mandelli et al., 2007; Aguilera et al., 2009; Karg et al., 2011). Hence, genetic inhibition 
of 5-HTT constitutes a risk factor for affective abnormalities in rodents, primates, and 
humans (Murphy et al., 2001; Hariri and Holmes, 2006; Canli and Lesch, 2007). 
However, blocking 5-HTT in adulthood using SSRIs produced decreased anxiety and 
depression-related behaviors in both humans and rodents (Dulawa and Hen, 2005; Berton 
and Nestler, 2006). Thus, lacking the 5-HTT throughout life produces opposite effects on 
behavior when compared to transiently blocking 5-HTT in adulthood. This leads to the 
hypothesis that genetically reduced 5-htt function during critical periods of development 
alter brain function in a way that predisposes the organism to affective behaviors later in 
life. This hypothesis is supported by research showing that the postnatal (P4) to P21 




treatment leads to increased anxiety and depression-like behavior in adulthood. The 
pharmacological effect was dependent on the presence of the 5-HTT, as no effect of FLX 
treatment was seen in 5-htt -/- mice (Ansorge et al., 2004). Furthermore, while early life 
blockade of 5-HTT increases anxiety and depression-like behavior in adult mice, 
transient FLX treatment in 3-month-old mice had no demonstrable effects on the same 
emotional behaviors after cessation of treatment (Ansorge et al., 2008).  
            Thus, the developmental component of 5-HTT blockade explains the contrasting 
effect of pharmacologic 5-HTT blockade during adulthood and genetic life-long 5-HTT 
inhibition. The results furthermore indicate that there exists a critical developmental time 
window during which 5-HTT blockade exerts its “negative” influence on adult behavior.  
 
I.V.VI. MAOA genetic life-long blockade vs pharmacological blockade 
            MAOA deficient mice display increased aggressive behavior and increased 
anxiety (Cases et al., 1995; Popova et al., 2001; Scott et al., 2008). Recently, 
hypomorphic MAOA mutant mice (MAO-A Neo) were generated, featuring the insertion 
of a floxed neomycin-resistance cassette in intron-12 of the maoa gene. MAO-A Neo 
mice show low levels of MAO-A enzymatic activity instead of complete ablation of 
MAOA. MAO-A Neo mice showed significant reductions in social interaction 
comparable to the KO mice even though the MAO-A Neo mice did not show increased 
aggressive behavior in resident-intruder aggression test (Bortolato et al., 2011).  
             Monoamine Oxidase inhibitor (MAOI) drugs play an important role in the 
treatment of anxiety and depression disorders and Parkinson’s disease (Youdim and 




(Thase et al., 1992; Nolen et al., 1993; Krishnan, 2007) and there is evidence that MAOIs 
are of more benefit than TCAs in treating patients with anxiety disorders (Sheehan et al., 
1980; Bakish, 1994; Krishnan, 2007). 
            The divergent effects of genetic lifelong inhibition versus pharmacologic 
inhibition during adulthood again leads to the thought that perturbed MAOA function 
during developmental might increase the likelihood of aggressive and anxiety traits later 
in life. 
 
I.VI 5-HT2A receptor  
            Serotonin signals through at least 14 receptors to exert its functions. Among these 
different receptors, 5-HT2 receptors are generally excitatory, couple positively to 
phospholipase C and stimulate the accumulation of inositol phosphates and intracellular 
Ca2+ (Berg et al., 1998; Sodhi and Sanders-Bush, 2004). The 5-HT2A receptor is a 
member of the super-family of 7-transmembrane-spanning (7-TMS) receptors, also 
known as G protein-coupled receptors. Traditionally it is thought that stimulation of the 
5-HT2A receptor will only activate phospholipase C in brain tissues via G-protein 
coupling (Sanders-Bush et al., 1988). Further studies have however shown that 5-HT2A 
receptors interact with diverse signaling pathways: Endogenously expressed 5-HT2A 
receptors activate phopholipase A2 (PLA2), phospholipase D (PLD), and the JaK/Stat 
pathways (Guillet-Deniau et al., 1997; Kurrasch-Orbaugh et al., 2003). In addition, they 
also inhibit or activate adenyl cyclase in certain cell systems (Garnovskaya et al., 1995; 





I.VI.I 5-HT2A receptor distribution 
            The presence and expression pattern of 5-HT2A receptors and htr2a, respectively 
has been mapped extensively by receptor autoradiography, in situ hybridization, and 
more recently, immunocytochemistry. In adult tissues, high levels of 5-HT2A binding 
sites are present in many forebrain regions, especially cortical areas (neocortex, 
entorhinal and pyriform cortex, claustrum), the caudate nucleus, the nucleus accumbens, 
the amygdala, the olfactory tubercle and the hippocampus, of all species studied (Pazos et 
al., 1985; Pazos and Palacios, 1985; Li et al., 2003). htr2a expression appears as early as 
embryonic day 9 and exists throughout lifetime (Lauder et al., 2000). htr2a expression 
increases with age and reaches a relatively stable level after P10-P11 in various brain 
stem nuclei (Liu and Wong-Riley, 2010). Immunochemistry analysis in rat also showed 
that 5-HT2A receptor abundance was at a low level at postnatal day 3 (P3) and increased 
greatly during the first 3 postnatal weeks reaching adult level at P21 (Li et al., 2004). 
This dynamic change of htr2a expression and 5-HT2A receptor abundance in brain 
regions implicated in emotional and cognitive processing indicates that early postnatal 5-
HT2A receptor signaling might be involved in mediating the trophic-like effects of 
developmetnal 5-HT signaling, which impact adult behavior.  
 
I.VI.II 5-HT2A receptor and anxiety/depression 
            The 5-HT2A receptor is involved in a number of different physiological functions 
including sleep, endocrine modulation, thermoregulation, pain modulation, cognitive 
function and memory (Harvey, 2003; Popa et al., 2005; Pawlyk et al., 2006; Morairty et 




disorders including anxiety, depression and schizophrenia (Leysen, 2004; Berg et al., 
2008; Kato et al., 2009; Ebdrup et al., 2011). In the context of my dissertation, I will 
focus on its role in anxiety and depression related behaviors. Human studies revealed that 
htr2a variants interact with childhood maternal nurturance to influence depressive 
symptoms in adulthood (Jokela et al., 2007). Depressive patients show up-regulation of 
frontal 5-HT2A receptors and down-regulation 5-HT2A receptor binding in the 
hippocampus (Massou et al., 1997; Mintun et al., 2004). Mice lacking 5-HT2A receptors 
show decreased anxiety in multiple behavior tests; in addition, cortical restoration of 
htr2a expression normalizes the anxiety phenotype (Weisstaub et al., 2006). 5-HT2A 
antagonists have anxiolytic effects in different behavior tests (Griebel et al., 1997a; 
Griebel et al., 1997b; Millan et al., 2003), even though some reports suggested an 









            MAOA catalyzes the oxidative deamination of bioamines including 5-HT, NE, 
and DA. MAOA transient blockade during adulthood has anti-depressant/anxiolytic 
effect (Youdim and Weinstock, 2004; Krishnan, 2007). Unlike the salutary effects of 
pharmacologic MAOA inhibition, constitutive mutations of maoa function result in a 
syndrome characterized by antisocial/aggressive behavior in humans (Brunner et al., 
1993a). Moreover, low expressing maoa variants are also associated with aggression and 
anxiety traits in rhesus macaques and humans (Tadic et al., 2003; Buckholtz and Meyer-
Lindenberg, 2008; Karere et al., 2009). Consistent with higher primates, mice with 
genetic inactivation of maoa exhibit heightened levels of aggression and neophobia 
(Cases et al., 1995; Scott et al., 2008; Godar et al., 2010). The divergent effects of genetic 
(lifelong) mutations versus pharmacologic inhibition (during adulthood) leads us to 
hypothesize that perturbed MAOA function during sensitive periods of brain maturation 
increases the likelihood of aggressive and anxiety traits later in life. 
            The role of monoamine signaling in brain development has been firmly 
established. During the embryonic and early postnatal period, monoamines act as trophic 
factors, modulating neurodevelopmental processes, such as cell division, migration, and 
differentiation (Gaspar et al., 2003; Homberg et al., 2010; Souza and Tropepe, 2011). In 
mice, genetic maoa ablation increases brain tissue concentrations of 5-HT, NE, and DA 




teratogenic consequence of murine maoa ablation, the disruption of barrel fields in the 
somatosensory cortex, has been linked to increased 5-HT signaling during perinatal 
development (Cases et al., 1996; Vitalis et al., 1998; Rebsam et al., 2002). Increased 5-
HT signaling during early postnatal development on the other hand increases 
anxiety/depression-like behavior including neophobia in adult mice (Ansorge et al., 2004; 
Ansorge et al., 2008). Thus, we hypothesized that increased 5-HT signaling during early 
postnatal development causes neophobia in maoa deficient mice. Furthermore, we 
predicted that the origins of aggressive behaviors are also developmental and postnatal, 
because re-expressing maoa from postnatal day P1 onwards restores normal aggressive 
behavior in conditional maoa knock-out mice (Chen et al., 2007). To test both hypotheses, 
we compared the effects of developmental MAOA inhibition and monoamine transporter 
blockade on adult behavior and monoamine signaling in mice. 
 
Materials and Methods 
Subjects.  
            Mice were injected intraperitoneally (i.p.) daily (2:00 pm - 5:00 pm) with vehicle 
(VEH, 0.9% NaCl, 5 ml/kg), fluoxetine (FLX, 10 mg/kg, 5 ml/kg), clorgiline (CLO, 20 
mg/kg), desipramine (DMI, 20 mg/kg) or GBR12909 (GBR, 20 mg/kg). FLX is a 5-HT 
transporter (5-HTT) blocker; CLO is a MAOA inhibitor; DMI is a norepinephrine 
transporter (NET) blocker; GBR12909 is a dopamine transporter (DAT) blocker. Groups 
of mice were injected during different postnatal periods: P2-P21 or P22-P41. Animals 
were maintained on a 12-hour light-dark cycle (lights on at 8 am) and provided with food 
and water ad libitum. Animal testing was conducted in accordance with the Principles of 




institutional animal committee guidelines. 
 
Drugs 
            For the studies involving postnatal drug administrations, fluoxetine (ANAWA 
Trading SA, Wangen, Switzerland), clorgiline (ANAWA Trading SA), desipramine 
(ANAWA Trading SA), GBR 12909 (ANAVA Trading SA) were dissolved in 0.9% 
NaCl to achieve the following concentrations: fluoxetine, 2 mg/ml; clorgiline, 4 mg/ml.; 
desipramine 4mg/ml; GBR12909 4mg/ml. Solutions were prepared fresh every day. FLX 
is a 5-HT transporter (5-HTT) blocker; CLO is a MAOA inhibitor; DMI is a 
norepinephrine transporter (NET) blocker; GBR12909 is a dopamine transporter (DAT) 
blocker. GBR12909 has a very high binding selectivity and long half-life (Andersen, 
1989; Ingwersen et al., 1993).  
 
Behavior Testing 
Anxiety/depression like behavioral testing 
All animals were exposed to the same series of behavioral paradigms starting at 3 months 
of age. The tests were administered in the following order: open field, novelty suppressed 
feeding, and shock avoidance with a minimum of 7 days between each test. All 
behavioral testing took place during the light cycle between 12:00pm and 7:00 pm. To 
eliminate odor cues, each apparatus was thoroughly cleaned after each animal. 
 
Open Field  




chambers as previously described (Ansorge et al., 2008). Mice were tested in Plexiglas 
activity chambers equipped with infrared beams located 1.5 cm above the chamber floor 
and spaced 2.5 cm apart to detect horizontal activity. Vertical activity was detected using 
another set of infrared beams affixed 6 cm above the chamber floor and spaced 2.5 cm 
apart. It consists of a simple square enclosure that is equipped with infrared detectors to 
track animal movement in the horizontal and vertical planes. The conflicting innate 
tendencies to avoid bright light and open spaces but explore novel environments 
influence locomotor behavior. Measures of total distance covered during locomotion are 
used as an index of activity, while the proportion of time or distance spent in the center is 
taken as a measure of anxiety. Mice were placed into the center of the open field and 
activity was recorded for 30 minutes. Testing took place under bright ambient light 
conditions. Total distance, total ambulatory time, and vertical activity were measured. 
 
Novelty-suppressed feeding 
            The novelty-suppressed feeding test is a behavior paradigm that is sensitive to 
chronic but not acute antidepressants as well as acute treatment with benzodiazepines 
(Bodnoff et al., 1989). The test was performed as described previously (Santarelli et al., 
2003): the testing apparatus consisted of a plastic box (50 x 50 x 20 cm). The floor was 
covered with 2 cm of wooden bedding. Twenty-four hours before behavioral testing, 
animals were deprived of all food in the home cage. At the time of testing, two food 
pellets were placed on a piece of round filter paper (12 cm diameter) positioned in the 
center of the box. The test began immediately after the animal was placed in a corner of 




time, 10 min). Immediately afterward, the animal was transferred back to its home cage 
and the amount of food consumed in 5 min was measured. Each mouse was weighed 
before food deprivation and before testing to assess the percentage of body weight loss. 
Immediately after initiating a feeding episode, mice were removed from the arena and 
placed into their home cage containing a pre-weighed food pellet and allowed to feed ad 




            Shock escape is the primary dependent measure affected by uncontrollable stress 
that occurs during a learned helplessness procedure (Seligman, 1972). Learned 
helplessness has been studied as a model of depression since shock avoidance 
performance is improved after antidepressant treatment (Cryan et al., 2002). Shock 
escape was performed in a 2-chambered Plexiglas shuttle box with the two chambers 
separated by an automated guillotine door as previously described(Lira et al., 2003). Each 
apparatus is located within a sound attenuated chamber. At the beginning of each trial, 
the door was raised and a mild scrambled foot shock (0.2 mA; 10 s duration) was 
delivered to the subject. The end of a trial was signaled by the closing of the guillotine 
door and was triggered either by a transition to the opposite chamber or after 10 s. 
Transition latencies were recorded. If the subject failed to make a transition during the 
10s duration of the foot shock, a maximum latency of 10 s was recorded. A session 
consisted of 30 trials separated by a 30 s inter-trial interval. Locomotor activity was 






Isolation induced aggression test 
            The aggression test used a rectangular cage that is divided in half by a perforated 
partition made of clear plastic. A pair of mice with the same treatment was placed into 
each compartment respectively. The mouse in one compartment is able to see, hear and 
smell the other mouse through the holes in the plastic divider, but physical interaction is 
blocked. Mice were housed for at least 10 days before experiment was performed. On test 
day, dividers were taken out and mice were allowed to freely interact for at least 10mins. 
All behaviors were videotaped. The latency to tail rattling, the latency to first attack, the 
total biting time, the total mounting time and the total tail rattling time were scored to 
assess aggressive behavior. The aggressive behavior is assessed by parameters adding up 
total biting time, and total mounting time and total tail rattling time.  
 
Locomotor activity in response to amphetamine 
            Adult mice were injected with amphetamine (3 mg/kg, i.p.) or VEH and 
locomotor activity was assessed in the open field. Mice were placed into the center of the 
Open Field chamber and freely run for 30 minutes. Immediately following this, mice 
were injected amphetamine at 3mg/kg and returned to the testing environment for 60 
minutes. 
 




            HPLC was carried out on several brain regions(Underwood et al., 1999). 
Concentrations of biogenic amines and metabolites were measured using reversed-phase 
high-performance liquid chromatography (HPLC) with electrochemical detection. The 
dissected brain samples in a 1.5-ml microfuge tube were homogenized in 0.5-1.0 ml of 
0.4M perchloric acid with an Ultra Cell Disruptor (Microson, NY).  The homogenate was 
centrifuged for 5 minutes at 14,000g in cold room and a 50 µl of typically four-fold 
diluted aliquot of the supernatant was injected over the HPLC system. The HPLC system, 
equipped with Waters Millennium software, consists of a Waters 515 HPLC pump, a 
Waters 717 Autosampler, a Varian Microsorb 100-5 C18 reverse-phase column 
(DYNAMAX 150x4.6 mm) attached with a Guard column (4.6 mm) and an ESA 
Coulochem electrochemical detector (Model 5100A) with a guard cell (Model 5020) and 
a dual analytical cell (Model 5011A).  The electrochemical detector was set at potential 
of +0.05 for the first cell and +0.5V for the second cell.  The mobile phase contained 0.75 
mM sodium phosphate (pH 3.1), 1.4 mM 1-Octanesulfonic acid, 10 µM sodium EDTA 
and 8% acetonitrile. The mobile phase was filtered through a Millipore 0.22 µm filter 
(Type GV) and degassed in vaccuo.  The flow rate was maintained at 0.8 ml/min. A 
chromatography software package (Waters Millennium) was used for data acquisition 
and analysis. Values are calculated based on peak area and compared to standard 
solutions.  The inter- and intra-assay coefficients of variation of the assay were each less 
than 5%. The sensitivity of the assay was less than 0.5 pmol/injection. No effect of 






            Statistical analysis was performed using StatView 5.0 software (SAS Institute, 
Cary, NC). Data were analyzed using Student’s t test, one-way, or two-way ANOVA 
with Student–Newman–Keuls posthoc testing; survival analysis, Kaplan-Meier, Logrank 
Mantel-Cox test; or non-parametric Mann-Whitney test as indicated. The criterion for 
significance for all analyses was p < 0.05. Results from data analyses are expressed as 
mean ± SEM. 
 
Results 
The effect of SERT and MAOA blockade during different developmental periods on 
adult anxiety/depression like behavior 
            Early postnatal 5-HTT blockade increases anxiety/depression-like behavior in 
mice (Ansorge et al., 2004; Ansorge et al., 2008). Because 5-HTT and MAOA blockade 
both increase 5-HT signaling, we hypothesized that early postnatal MAOA blockade 
would also increase adult anxiety/depression-like behavior. To test this hypothesis, we 
treated mice with the 5-HT transporter blocker fluoxetine (FLX, 10 mg/kg/day, i.p.), the 
MAOA inhibitor clorgiline (CLO, 20 mg/kg/day, i.p.), or vehicle (VEH, 0.9% NaCl, i.p.) 
in the early postnatal period (PN), from postnatal day 2 to 21 (P2-P21) and assessed 
emotional behavior in adulthood (P90). To investigate developmental specificity, we also 
tested mice treated with FLX, CLO, and VEH in the peri-adolescent period (ADO), from 
postnatal day 22 to 41 (P22-P41). To control for the effects of the injection procedure, we 
included naïve littermates in our behavioral tests. 
            Using the novel open field, we assessed neophobic behaviors by measuring 




total ambulatory time (treatment effect: F(2,127) = 6.225, p = 0.0026) and total time spent 
rearing (treatment effect: F(2,127) = 5.42, p = 0.0055; developmental timing effect: F(1,127) 
= 13.56, p = 0.0003) when compared to VEH-treated mice (Figure 2-1). Neither FLX nor 
CLO treatment from P22-P41 altered exploratory behavior compared with VEH treated 
mice. Behavior between VEH-treated mice and naïve littermates did not differ in either 
measure. 
            To further probe neophobia phenotypes, we used the novelty suppressed feeding 
paradigm, which assesses approach-avoidance behavior when a food-deprived animal is 
presented with a familiar food pellet placed in the center of a brightly-lit novel arena. 
Mice exposed to FLX or CLO from P2-P21 exhibited longer latencies to approach and 
feed when compared to PN-VEH controls (treatment effect: p = 0.0001, survival analysis, 
Kaplan-Meier, Logrank Mantel-Cox) (Figure 2-2a). However, neither FLX treatment nor 
CLO treatment from P22-P41 produced such behavioral effect. No effect for treatment, 
developmental timing or treatment x developmental timing was detected for weight loss 
during food deprivation (Figure 2-2b). Behavior between VEH-treated mice and naïve 
littermates did not differ in either measure. 
            To assess behavioral response to stress, we examined escape latency in the shock 
escape paradigm. Consistent with our findings in tests of neophobia, mice exposed to 
FLX or CLO from P2-P21 but not P22-P41 exhibited significantly increased escape 
latencies when compared to PN-VEH controls (treatment effect: F(2,133) = 21.106, p < 
0.0001; developmental timing effect: F(1,133) = 46.749, p < 0.0001; treatment x 
developmental timing interaction: F(2,133) = 24.613, p < 0.0001) (Figure 2-3a). No effect 




pre-shock activity in the dark chambers with the door open (Figure 2-3b), indicating that 
the effect on escape latencies was not caused by reduced overall activity. Behavior 
between VEH-treated mice and naïve littermates did not differ in either measure. 
 
Figure 2-1 Exploratory behavior in the open field. In the open field, the following 




and vertical activity(C). FLX or CLO treatment from P2-P21 reduced the distance 
ambulating (A), the time ambulating (B) and the time rearing (C) when compared to 
control mice treated with VEH from P2-P21.*, p<0.05; **, p<0.01; ***, p<0.001 
compared with their respective controls. n = 19 - 32 mice per group. veh, vehicle; flx, 
Fluoxetine.
 
Figure 2-2. Novelty-suppressed feeding test. (A) The latency to begin feeding is shown in 
seconds. (B) Weight loss is expressed as a percentage of free-feeding body weight. n = 19 
- 32 mice per group. FLX or CLO treatment from P2-P21 increased the latency to feed 
when compared to control mice treated with VEH from P2-P21 (A). No effect of 
treatment, period, or treatment x period interaction was detected for the weight loss after 
24 hours of food deprivation (B).  ***, p<0.001 compared with their respective controls. 





Figure 2-3. Shock escape paradigm. (A) Average latency to escape a foot shock shown in 
seconds. (B) Locomotor activity before shocks. n = 19 – 32 mice per group. FLX or CLO 
treatment from P2-P21 increased the latency to escape when compared to control mice 
treated with VEH from P2-P21 (A). No effect of treatment, period, or treatment x period 
interaction was detected for activity in the shuttle box before the onset of shock (B) *, 
p<0.05; **, P<0.01;  ***, p<0.001 compared with their PN-VEH controls. veh, vehicle; 






The effect of 5-HTT and MAOA blockade during different developmental periods on 
adult aggressive behavior  
            Next we investigated aggressive behaviors in adult mice that had received FLX, 
CLO, or VEH during early postnatal or peri-adolescent development using the isolation-
induced aggression paradigm. We measured the time mouse pairs spent engaged in 
aggressive behaviors consisting of mounting, tail rattling, or biting.  
            We found that CLO treatment from P22-P41 but not from P2-P21 increased 
aggressive behavior, when compared to VEH controls (effect of treatment: F(2,69) = 7.258, 
p = 0.0014; effect of developmental timing: F(1,69) = 4.737, p = 0.033; treatment x 
developmental timing interaction: F(2,69) = 3.828, p = 0.0265) (Figure 2-4). FLX 
treatment reduced aggressive behavior when compared to VEH treatment, with no 
indication of developmental timing specificity. Aggressive behavior between VEH-
treated mice and naïve littermates did not differ. 
            In summary, PN-FLX or PN-CLO treatment from P2 to P21 produced increased 
anxiety behavior; while adolescent FLX or CLO treatment from P22 to P41 did not 
produce increased anxiety behavior. Adolescent CLO treatment but not FLX treatment 
from P22 to P41 resulted in increased aggression behavior, while PN-FLX or PN-CLO 








Figure 2-4. Altered aggression after developmental 5-HTT or MAOA blockade. 
Isolation induced aggressive behavior was assessed in mice by scoring the time spent 
mounting, tail rattling, or biting during a 10-minute encounter. Aggressive behavior was 
increased in mice treated with CLO from P22-P41 when compared to control mice 
treated with VEH from P22-P41. Mice treated with FLX displayed reduced aggression 
when compared to VEH-treated control mice. Of note, FLX treated mice did not display 
any tail rattling or biting behavior. (n = 7–16 pairs per group). (*p < 0.05; **p < 0.01, 
***p < 0.001). 
 
Peri-adolescent MAOA blockade reduces the metabolism of 5-HT, NE and DA. 
            The differential consequences of P22-P41 5-HTT and MAOA blockade on adult 
aggressive behavior suggest that non-5-HTgic effects of peri-adolescent MAOA blockade 
increase adult aggression. In peri-adolescence, maoa is expressed in 5-HTergic, DAergic 
and NEergic neurons (Vitalis et al., 2002). To determine the consequences of P22-P41 
CLO treatment on brain monoamine signaling, we assessed tissue monoamine and 
metabolite levels at P23 (24h after treatment initiation) and at P42 (24 h after treatment 




Hydroxyindoleacetic acid (5-HIAA), DA and its two main metabolites 3,4-
Dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and NE. 
            CLO treatment significantly increased 5-HT and reduced 5-HIAA levels in the 
brain stem at P23 (F(1,12) = 51.972, p < 0.0001 and F(1,12) = 31.92, p = 0.0001, 
respectively) and P42 (F(1,11) = 62.475, p < 0.0001 and F(1,11) = 18.8, p = 0.0012, 
respectively), when compared to VEH treated controls (Figure 2-5, Figure 2-S2 and 
Table S1). Norepinephrine (NE) levels in the brainstem were also increased by CLO 
treatment at P23 and P42 (F(1,12) = 68.717, p < 0.0001 and F(1,11) = 40.45, p < 0.0001, 
respectively) (Figure 2-5, Figure 2-S2 and Table S1). Striatal DA levels were not affected 
at P23 and significantly increased at P42 after chronic CLO treatment when compared to 
VEH treated controls (F(1,12) = 0.033, p = 0.8587 and F(1,11) = 61.745, p < 0.0001, 
respectively) (Figure 2-5, Figure 2-S3 and table S1). Striatal DOPAC levels were lowered 
at P23 and P42 (F(1,12) = 30.292, p = 0.0001 and F(1,11) = 13.444, p = 0.0037, respectively), 
while HVA levels were unchanged (F(1,12) = 0.003, p = 0.9586 and F(1,11) = 2.41, p = 
0.1489, respectively) (Figure 2-5, Figure 2-S3 and Table S1). These data demonstrate that 
MAOA blockade using CLO treatment during peri-adolescence inhibits 5-HT, NE, and 
DA metabolism. 
 
Peri-adolescent MAOA but not 5-HTT blockade reduces adult brainstem 5-HIAA levels 
and increases striatal DA and DOPAC levels. 
            To further investigate the differential effect of peri-adolescent MAOA and 5-HTT 
blockade on adult aggressive behavior, we next examined if either treatment produces 




significantly reduced 5-HIAA levels in the brain stem at P180 when compared to either 
VEH- or FLX-treatment (F(2,15) = 8.505, p = 0.0034) (Figure 2-5, Figure 2-S1 and Table 
S1). P22-P41 CLO treatment also significantly increased striatal DA (F(2,15) = 4.085, p = 
0.0384) and DOPAC levels (F(2,15) = 5.847, p < 0.0133) at P180 when compared to VEH-
treatment and VEH- or FLX-treatment, respectively (Figure 2-5, Figure 2-S1 and Table 
S1). Peri-adolescent FLX treatment did not produce significant changes in monoamines 






Figure 2-5. Altered monoamine and –metabolite levels during and after peri-adolescent 
MAOA blockade. Tissue 5-HT, 5-HIAA, NE, DA, DOPAC, and HVA levels were 
measured by high performance liquid chromatography. (a) Mice were injected daily with 
CLO or FLX from P22-P41 and aggressive behaviors were investigated after P120. (b) 
Monoamine and –metabolite levels were assessed at P23, P42, and P180 in brain stem 
and striatum. Monoamine levels were increased and monoamine-metabolite levels were 
decreased during CLO treatment when compared to VEH treatment as indicated. At P180, 
brain stem 5-HIAA levels were decreased and striatal DA and DOPAC levels were 
increased after CLO treatment when compared to VEH treatment. FLX treatment did not 
alter monoamine or –metabolite levels at P180 when compared to VEH treatment. (n = 
5–8 mice per group; colored fields indicate differences compared  to VEH with p at least 
< 0.05). 
 
Peri-adolescent MAOA blockade increases while 5-HTT blockade reduces the behavioral 
response to amphetamine in adulthood. 
            Dopaminergic hyper-activity has been implicated in aggression (de Almeida et al., 
2005). We find that peri-adolescent MAOA blockade increases aggression and striatal 
DA and DOPAC levels in adulthood. Hence we hypothesized that peri-adolescent 
MAOA blockade produces long-lasting changes in the DA system. Conversely, we find 
that peri-adolescent 5-HTT blockade reduces adult aggression without altering striatal 
DA or DOPAC levels and might thus have no effect on the DA system. To test this 
hypothesized dissociation, we investigated the behavioral response to amphetamine 
challenge (3 mg/kg, i.p.) in adult mice (P180), which had received VEH, FLX, or CLO 
during P22-P41. We detected an effect of adult amphetamine treatment, an effect of peri-
adolescent treatment and an interaction between both treatments (F(16,480) = 8.06, p < 
0.0001; F(2,30) = 8.4, p = 0.0013 and F(16,480) = 4.141, p < 0.0001, respectively) (Figure 2-
6a). Adult VEH injection did not alter behavior in either of the P22-P41 treated groups 
(Figure 2-6b). Adult AMPH injection did alter behavior differentially in the P22-P41 




mice showed a significantly increased response to amphetamine (peri-adolescent x adult 
treatment interaction: F(16,416) = 3.810, p < 0.0001)  (Figure 2-6a). Conversely, P22-P41 
FLX treated mice showed a significantly reduced response to amphetamine when 
compared to P22-P41 VEH treated littermates (peri-adolescent x adult treatment 
interaction: F(16,288) = 1.896, p = 0.0375)  (Figure 2-6a). These data demonstrate that P22-
P41 CLO and FLX treatment differentially impact the sensitivity of the adult DA system. 







Figure 2-6 Altered behavioral response to amphetamine in adulthood after peri-
adolescent MAOA or 5-HTT blockade. Behavioral amphetamine response was assessed 
in ADO-CLO, ADO-FLX and ADO-VEH treated mice using the open field.  (a) 
Amphetamine injection (3 mg/kg) induced locomotor hyperactivity in ADO-VEH and 
ADO-CLO, but not in ADO-FLX treated mice. The behavioral response to amphetamine 
challenge in ADO-CLO treated mice was increased when compared to ADO-VEH 
treated controls. (b) VEH injection did not alter locomotor activity in any of the three 
treatment groups. (n = 5-15 per group) (posthoc comparisons indicate statistically 







Peri-adolescent DAT but not NET blockade increases adult aggressive behavior. 
            Next we sought to identify the monoamine component in P22-P41 MAOA 
blockade, which leads to increased adult aggressive behavior. Because peri-adolescent 
MAOA blockade robustly increases central 5-HT, NE and DA levels, we examined 
whether increased peri-adolescent NE or DA signaling could increase adult aggressive 
behavior. To selectively and transiently increase NE or DA signaling we administered 
drugs blocking the NE transporter (NET) and the DA transporter (DAT). We used 
desipramine (DMI, 20 mg/kg/day) to block the NET and GBR12909 (GBR, 20 
mg/kg/day) to block the DAT. DMI treatment from P22-P41, either alone or in 
combination with FLX treatment, did not result in increased aggressive behavior in 
adulthood (Figure 2-7a). GBR treatment from P22-P41 however lead to increased time 
spent in active aggressive behaviors (Mann Whitney, p = 0.0104) (Figure 2-7b). 
 
Peri-adolescent DAT blockade increases behavioral response to amphetamine in 
adulthood. 
             Finally, we tested whether peri-adolescent GBR treatment produces long-lasting 
changes in the DA system, which mimic the effect of MAOA blockade. Strengthening 
the correlation between aggressive behavior and a sensitized/hyper-active DA system, we 
indeed found that P22-P41 GBR treated mice display an exaggerated response to adult 
amphetamine treatment when compared to adult VEH injection or P22-P41 VEH treated 




treatment x adult amphetamine challenge interaction: F(16,160) = 3.119, p = 0.0001, 




Figure 2-7 Increased adult aggressive behavior and response to amphetamine challenge 
after peri-adolescent DAT blockade. Isolation induced aggressive behavior was assessed 
in mice by scoring the time spent mounting, tail rattling, or biting during a 10 minute 
encounter (a, b). Behavioral amphetamine response was assessed in mice using the open 
field (c, d).  Aggressive behavior was not altered in mice treated with DMI or DMI+FLX 
from P22-P41 when compared to VEH treated control mice (n = 5-15 per group) (a). 
Aggressive behavior was increased in mice treated with GBR from P22-P41 when 
compared to VEH treated control mice (n = 11 per group) (b). (c) Amphetamine injection 
(3 mg/kg) induced locomotor hyperactivity in ADO-VEH and ADO-GBR treated mice. 
The behavioral response to amphetamine challenge in ADO-GBR treated mice were 
increased when compared to ADO-VEH treated controls (n = 6 per group; posthoc 




adolescent treatment). (d) VEH injection did not alter locomotor activity in ADO-GBR or 
ADO-VEH treated mice (n = 6 per group). (*p < 0.05, ***p < 0.001).  
 
Table S1. Monoamine and –metabolite levels during and after peri-adolecent MAOA or 
5-HTT blockade. Tissure 5-HT, 5-HIAA, NE, DA, DOPAC, and HVA levels were 
measured by high performance iquid chromatography. (n=5-8 mice per group; colored 






Figure 2-S1 Altered monoamine and –metabolite levels in adulthood after peri-adolescent 
MAOA blockade or 5-HTT blockade. Tissue 5-HT, 5-HIAA, NE, DA, DOPAC, and 
HVA levels were measured by high performance liquid chromatography. Mice were 
injected daily with CLO or FLX from P22-P41 and monoamine and –metabolite levels 
were assessed at P180 in brain stem and striatum. At P180, brain stem 5-HIAA levels 
were decreased and striatal DA and DOPAC levels were increased after CLO treatment 
when compared to VEH treatment. FLX treatment did not alter monoamine or –






Figure 2-S2. Altered monoamine and –metabolite levels during and after peri-adolescent 
MAOA blockade or 5-HTT blockade. Tissue DA, DOPAC, and HVA levels were 
measured by high performance liquid chromatography. Mice were injected daily with 
CLO or FLX from P22-P41 and Monoamine and –metabolite levels were assessed at P23 
(A), P42 (B) in brain stem and striatum. At P23, DOPAC levels were decreased after 
CLO treatment. At P42, DA levels were increased and DOPAC levels were decreased 











Figure 2-S3. Altered monoamine and –metabolite levels during and after peri-adolescent 
MAOA blockade or SERT blockade. Tissue 5-HT, 5-HIAA, and NE levels were 
measured by high performance liquid chromatography. Mice were injected daily with 
CLO or FLX from P22-P41 and Monoamine and –metabolite levels were assessed at P23 
(A), P42 (B) in brain stem. At P23, NE levels and 5-HT levels were increased and 5-
HIAA levels were decreased after CLO treatment; At P42, NE and 5-HT levels were 
increased and 5-HIAA levels were decreased after CLO treatment when compared to 







            Our experiments demonstrate the existence of two developmental periods 
whereupon early-life perturbation of monoamine signaling alters adult behavior: an early 
postnatal (P2-P21) 5-HT-sensitive period that affects anxiety and depression-related 
behaviors and a later peri-adolescent (P22-P41) DA-sensitive period altering aggression.  
Moreover, serotonergic and dopaminergic signaling perturbations during peri-
adolescence also exert profound and opposing effects on the behavioral response to 
psychostimulants.  
            Our findings can explain the paradoxical high neophobia/anxiety phenotypes of 5-
htt-/- mice (Holmes et al., 2003; Lira et al., 2003), maoa-/- mice (Cases et al., 1995; Scott 
et al., 2008; Godar et al., 2010), and pre-synaptic htr1a deficient mice (Richardson-Jones 
et al., 2011), because these mouse lines lack their respective gene products throughout 
life, including P2-P21. Likewise, the model can explain the increased aggression seen in 
constitutive maoa, dat, and comt loss-of-function mouse lines (Cases et al., 1995; Gogos 
et al., 1998; Rodriguiz et al., 2004; Scott et al., 2008). The moderating effect of 
developmental 5-HTT blockade on adult aggressive behavior does not follow the strict 
timing specificity (5-HTT blockade during P2-P21 or P22-P41 both decreased adult 
aggression), but nonetheless supports a developmental mechanism for the low-aggression 
phenotype of 5-htt-/- mice (Holmes et al., 2002a).  
            Our findings also comport with human vulnerabilities to anxiety, depression, and 
aggression conferred by functional genetic polymorphisms. For example, 




for the 5-htt (Lesch et al., 1996; Canli and Lesch, 2007; Risch et al., 2009; Caspi et al., 
2010; Karg et al., 2011), maoa (Schmidt et al., 2000; Tadic et al., 2003) and presynaptic 
htr1a (Le Francois et al., 2008). Likewise, aggressive behavior has been associated with 
loss-of-function and low-expressing maoa alleles (Brunner et al., 1993a; Caspi et al., 
2002; Zalsman et al., 2005; Buckholtz and Meyer-Lindenberg, 2008), the 10R variant of 
dat1 (Guo et al., 2007; Bedard et al., 2010), and the low activity met allele of the comt 
(Volavka et al., 2004). Our model predicts that these risk alleles act primarily during 
sensitive developmental periods to alter brain maturation and circuit formation leading to 
altered behaviors. The temporal dynamics of transcription in the human brain and their 
genetic moderation support this hypothesis (Colantuoni et al., 2011).  
            Based on our data, pharmacologic interventions during sensitive periods of human 
development would be predicted to impact affective and aggressive behavior. The murine 
P2-P21 period roughly corresponds to the third trimester of human gestation and early 
childhood, while P22-P41 corresponds to peri-adolescent development. Thus SSRIs taken 
by pregnant mothers might impact fetal brain maturation and adult affective behavior 
while stimulant exposure during peri-adolescence could alter adult aggressive behavior. 
Indeed, chronic stimulant exposure increases aggressive behavior in rodents, non-human 
primates and humans (Martin et al., 1990; Sokolov et al., 2004; Dawe et al., 2009), even 
in abstinent stimulant users (Sekine et al., 2006). The long-term effects of gestational 
SSRI exposure on affect, aggression, and cognition are unknown (Oberlander et al., 2009; 
Homberg et al., 2010), but prenatal SSRI exposure has been associated with a 2-fold 




            Our findings support the fundamental notion that circuitry and consequently 
behavior is most vulnerable to long lasting modulation during periods of maturation and 
high plasticity (Hensch, 2004; Crews et al., 2007). The 5-HT sensitive period described 
here coincides with the emergence of anxiety- and fear-related behaviors in rodents and 
the maturation of the underlying circuitry. For example, at around P10 the consequence 
of odor shock conditioning switches from preference to aversion, with amygdala 
engagement hypothalamic-pituitary-adrenal axis integration (Sullivan et al., 2000; 
Moriceau and Sullivan, 2006). Limbic structures including amygdala, prefrontal cortex 
and hippocampus are maturing during postnatal development and human s allele carriers 
as well as 5-htt-/- mice exhibit disrupted mPFC-amygdala functional connectivity that 
likely arises during early circuit maturation (Heinz et al., 2005; Pezawas et al., 2005). 
The DA-sensitive, peri-adolescent period coincides with the developmental onset of play 
fighting in rodents (Pellis and Pellis, 1997; Pellis and Pasztor, 1999) and non-human 
primates (Suomi, 2006), and human adolescence is characterized by dynamic changes in 
aggressive behavior (Moffitt, 1993). Adolescent rodents spend more time in social 
interactions (Primus and Kellogg, 1989). The quality of the social interaction changes 
during adolescent period. For example, rats engage in more complex defensive strategies 
(Pellis and Pellis, 1997) and exhibit differential rates of attack and defense in play 
fighting during adolescent developmental period (Pellis and Pellis, 1990). Since the brain 
maturation continues until adolescent period, the development of brain circuits makes this 
age period critically vulnerable with respect to impulse control and development of social 
behavior. Neural chemical disturbances during this developmental period lead to 




            Dopamine has been associated with a series of neuropsychiatric disorders. The 
dopamine transporter (DAT) gene variant has been implicated in ADHD (Todd et al., 
2005), schizophrenia (Saiz et al., 2010), bipolar disorders (Pinsonneault et al., 2011), and 
cocaine abuse (Guindalini et al., 2006). Mice lacking DAT have shown hyperlocomotion 
(Giros et al., 1996) and exhibited increased rates of reactivity aggression following mild 
social contact (Rodriguiz et al., 2004). A broad spectrum of psychiatric disorders 
involves inappropriate social interactions that could lead to heightened state of 
aggressiveness. Cocaine, which inhibits dopamine uptake (Horn, 1990), administered 
during adolescent developmental period (P27-P57) results in highly escalated aggression 
behavior (Harrison et al., 2000). In addition, adolescent cocaine exposure leads to 
significant deficits in serotonin afferent innervations to many brain areas implicated in 
aggression (DeLeon et al., 2002). Our study has directly shown that DAT blockade 
during adolescent period leads to increased aggressive behavior in adult mice. Dopamine 
system during adolescence has undergone evident changes such as increased prefrontal 
cortex fiber density (Kalsbeek et al., 1988) and pruning of DA receptors (Teicher et al., 
1995; Tarazi et al., 1998a, b). Increased dopaminergic tone by pharmacological treatment 
during this period might alter development of the structure and function of the brain and 
lead to changes of response towards social stimuli. This finding for the first time linked 
the developmental dopamine function manipulation to adult aggressive behavior. This 
finding also provides support for the notion that genetic polymorphisms of DAT gene 
may exert their effects during adolescent development of neuronal system by altering 




            We report that increased adult aggressive behavior elicited by peri-adolescent 
MAOA or DAT blockade correlates with increased locomotor-stimulating effects of 
amphetamine challenge in adulthood. Conversely, reduced adult aggressive behavior 
elicited by peri-adolescent 5-HTT blockade correlates with decreased locomotor-
stimulating effects of amphetamine challenge in adulthood. Supporting phylogenetic 
conservation, human individuals with antisocial traits also show mesolimbic dopamine 
hypersensitivity to amphetamine, as impulsivity is positively correlated with the 
magnitude of amphetamine-induced DA release in the striatum (Buckholtz et al., 2010). 
Highlighting the notion that altered DAergic signaling impacts adult behavior as a 
function of developmental timing, transient pre-adolescent methylphenidate exposure 
decreases responsiveness to cocaine’s locomotor-activating effects in adult rats 
(Andersen et al., 2002). Furthermore, transient adult methylphenidate exposure does not 
alter cocaine’s locomotor-activating effects in later adulthood (Andersen et al., 2002).  
Taken together, our findings support the existence of sensitive periods that influence life-
long vulnerability to anxiety, depression, aggression, and substance abuse. Such sensitive 
periods have been most extensively characterized for sensory systems (e.g. visual cortex), 
but conceptually similar principles may apply to the development and organization of 
brain circuitry that mediate the more complex behaviors described here. Furthering our 
knowledge of sensitive periods that determine the developmental trajectory of complex 
behaviors is a necessary step towards improving prevention and treatment approaches for 





Considerations and remarks 
            Here we show that peri-adolescent MAOA blockade or DAT blockade (P22-P41) 
produced increased aggressive behavior, and adult MAOA blockade or DAT blockade 
does not increase aggressive behavior (unpublished data, Qinghui Yu). This points to a 
specific time window that is contained within P22-P41 period, during which increased 
dopamine signaling would impact adult aggressive behavior. Thus it is worthwhile 
further redefining this critical time window to probe the developmental events 
responsible for altered aggressive behavior.  
            Although the current study suggests that dopamine hyper activity might be the 
mechanisms underlying this aggressive behavior elicited by peri-adolescent MAOA 
blockade, the exact mechanisms are far from clear. For example, what brain areas might 
be relevant to this behavior readout? What receptors or signaling pathways or genes 
might mediate the increased dopamine on aggressive behavior? What physiological 
changes are the direct impacts of DAT blockade? Future characterization of the 
morphology, structure, and physiology would be necessary.  
            Another important and interesting consideration is whether we can reverse or 
rescue the changes exerted by peri-adolescent MAOA blockade. Optogenetic stimulation 
of the neurons in the ventromedial hypothalamus, ventrolateral subdivison (VMHvl) 
causes male mice to initiate attack and pharmacogenetic silencing of VMHvl reversibly 
inhibits inter-male aggression. Would silencing of the neurons in VMHvl or lesions of 
this region rescue the behavior phenotype in peri-adolescent MAOA inhibitor treated 




stimulation of the PFC neurons rescue the behavior changes? Answering these questions 




Chapter III Early life blockade of 5-HTT on adult affective behavior and adult 
antidepressant-related behavioral response 
 
Introduction 
            Genetic factors that impact serotonin levels alter adult emotional behavior both in 
humans and in animals (D'Souza and Craig, 2006; Kim et al., 2006). Low 5-htt 
expression for example is associated with elevated trait anxiety and increased 
vulnerability to affective disorders (Lesch et al., 1996; Sen et al., 2004). However, 
pharmacologic inhibition of 5-HTT in adulthood generally produces therapeutic effects 
and ameliorates anxiety/depression symptoms (Dulawa and Hen, 2005; Berton and 
Nestler, 2006). This paradox led to the hypothesis that reduced 5-HTT function during 
critical periods of development may alter brain function in such a way as to predispose 
the organism to affective disorders later in life.  
              In support of this developmental hypothesis of anxiety and depression, it has 
been demonstrated that postnatal (P4) to P21 5-HTT blockade (using SSRIs) (Ansorge et 
al., 2004) or MAOA blockade (using the MAOA inhibitor clorgiline) (Qinghui Yu, 
Chapter II) increases depression/anxiety behavior in adult mice. The pharmacological 
effect of SSRIs is dependent on the presence of the 5-HTT, as no effect of treatment was 
seen in 5-htt -/- mice (Ansorge et al., 2004). Furthermore, while early life blockade of 5-
HTT increases anxiety and depression-like behavior in adult mice, transient FLX 
treatment in 3-month-old mice had no demonstrable effects on the same emotional 




increased 5-HT signaling during a critical time window (P4-P21) increases anxiety and 
depression-like behavior.   
              To better understand the manner in which increased 5-HT signaling during early 
life increases anxiety/depression-like behaviors, we further refined the developmentally 
sensitive period that confers the altered adult phenotype. We hypothesize that only a 
small period of exposure within P4-P21 is required to produce the same behavior effect 
as FLX treatment from P4-P21. We subdivided this period into P2-P11 or P12-P21, 
treated animals with FLX during these different postnatal periods and examined their 
anxiety- and depression-like behaviors in adulthood. In addition, we determined whether 
the increased anxiety/depression behavior could be normalized with adult SSRIs 
treatment.  
 
Materials and methods 
Animals 
              Pups were injected intraperitoneally daily (2:00 pm -5:00 pm) with either vehicle 
(0.9% NaCl, 5ml/kg) or FLX (10 mg/kg, 5ml/kg) during different postnatal periods P2-
P11, P12-P21, P2-P21, P22-P41. Mice were treated once per day for all these 
experiments. For treatment, entire litters were removed from dams and placed into a petri 
dish (10 cm diameter) containing shavings from the respective home cage. The petri dish 
was resting on scales, to allow for weighing mice after picking them up. Mice were 
injected in random order, and an entire litter was injected within 2 min. Immediately after 
injection, mice were placed back into the home cage. 




intraperitoneally daily (2:00 pm -5:00 pm) with either vehicle (0.9% NaCl, 5ml/kg) or 
FLX (10 mg/kg, 5ml/kg). Mice were treated individually once per day for four weeks 
before we started to test them in behavior tests. While testing for behavior, mice were 
also injected each day after behavior tests.  
           WT (129S6/SvEv) mice used for breeding were purchased from Taconic Farms. 
Animals were maintained on a 12-hour light-dark cycle (lights on at 8am) and provided 
with food and water. Animal testing was conducted in accordance with the Principles of 
Laboratory Animal Care National Institute of Health (NIH) guidelines and the 
institutional animal committee guidelines. 
 
Drugs 
            For the studies involving postnatal drug administrations, fluoxetine (ANAWA 
Trading SA, Wangen, Switzerland) was dissolved in 0.9% NaCl to achieve the following 
concentrations: fluoxetine, 2 mg/ml. Fluoxetine is a 5-HT transporter (SERT) blocker. 
Fluoxetine is chosen due to its high specificity to SERT and its long half-life. PNFLX 
treatment schedule (10 mg/kg/day, i.p.) into mouse pups, produces blood levels that are 
in the expected therapeutic range for humans (Ansorge et al., 2004; Ansorge et al., 2008) 
and constitute the minimum dose behaviorally active in mice (Dulawa et al., 2004) 
 
Behavior Testing 






            Data were analyzed using either Student’s t-test, one-way or two-way analysis of 
variance (ANOVA). Adult treatments or postnatal treatments were assessed as the 
independent variable. The criterion for significance of all analyses is p<0.05. All 
experiment results are expressed as mean± SEM. 
 
Results 
The effect of PN-FLX treatment on exploratory activity in novel environment 
            Early postnatal SERT blockade from P4-P21 increases anxiety/depression-like 
behavior in mice (Ansorge et al., 2004; Ansorge et al., 2008). To further redefine the 
critical time window during which early life blockade of SERT results in increased 
anxiety/depression like behavior, we treated mice with SERT inhibitor FLX 
(10mg/kg/day, i.p.) or vehicle (VEH, 0.9% NaCl, i.p.) from P2-P21, P2-P11, P12-P21, or 
P22-P41, and tested the anxiety and depression like behaviors in adult mice. To control 
for the injection stress, we also tested the naïve mice in our experiment. We first assessed 
exploratory behavior phenotype in the open field. In comparison to vehicle treated mice, 
PN-FLX treatment from P2 to P21 significantly decreased exploratory behavior in 
adulthood.  This was demonstrated by a reduction in the total distance travelled (Figure 
3-1A; Posthoc analysis p=0.0073), time spent ambulating (Figure 3-1B; Posthoc analysis 
p=0.0079), and rearing in the open field (Figure 3-1C; Posthoc analysis P=0.0463).  In 
addition, PN-FLX treated mice from P2 to P11 exhibit significantly decreased 
exploratory behavior in ambulatory distance (Figure 3-1A; p=0.0002), time spent 
ambulating (Figure 3-1B; p=0.0005), and rearing activity (Figure 3-1C; p=0.0397), which 




behavior is not elicited in other groups who are treated with FLX from P22 to P41 or P12 
to P21. This supports our hypothesis that a smaller time window (P2-P11) exists during 
which PN-FLX results in deficit in exploratory behaviors. The effects of PN-FLX was 
specific to exploratory behavior since we did not detect any differences in measures 
indicating anxiety level such as percentage of distance travelled in the center relative to 
the total distance traveled (Figure 3‐1S).  
 
The effect of PN-FLX treatment in test sensitive to chronic antidepressant treatment 
            To further assess the effect of PN-FLX treatment on adult emotional functioning, 
we examined their behavior in the novelty-suppressed feeding paradigm. This test is 
sensitive to chronic but not acute antidepressants as well as anxiolytics (Bodnoff et al., 
1989). In the NSF, food-deprived mice are presented with a familiar food pellet in a 
novel, brightly lit environment and the latency to approach the food and begin a feeding 
bout is recorded. Consistent with previous findings, PN-FLX treatment from P2 to P21 
prolonged the latency to feed (Figure 3-2A; p=0.0962). PN-FLX treatment from P2 to 
P11 significantly increased the latency to feed (Figure 3-2A; p<0.0001). PN-FLX 
treatment from P22 to P41 and from P12 to P21 does not produce the behavior deficit 
(Figure 2-2A). Weight losses during food deprivation and home cage food consumption 
were comparable across groups (Figure 3-2B), indicating the observed differences are not 
due to hunger levels.  
 




            We next examined the effects of PN-FLX in shock avoidance, a paradigm that 
assesses behavioral responses to stress. PN-FLX treatment from P2 to P21 produce 
behavior deficit in this paradigm as indicated by prolonged latency to escape shock 
(Figure 3-3A; p=0.0061). In addition, we found mice given FLX from P2 to P11 
exhibited significant impairment in shock escape test (Figure 3-3A; p<0.0001). In 
contrast, PN-FLX treatments during other later postnatal periods do not produce this 
behavior deficit. No effect of treatment was detected for pre-shock activity in the dark 
chambers with the door open (Figure 3-3B), indicating that the effect on escape latencies 
was not caused by reduced overall activity. 
 
The effect of adult FLX treatment in Postnatal treated mice  
            We next examined whether PN-FLX treated mice would response to adult 
antidepressant treatment. Since SSRIs are the most commonly prescribed anti-depressants, 
we gave mice chronic (>4 weeks) FLX treatment at 3-4 month old mice and tested the 
mice in novelty-suppressed feeding test. This test pharmacologically validated, sensitive 
to chronic but not acute antidepressants as well as anxiolytics. It has been previously 
demonstrated in 129 WT mice that adult chronic FLX treatment reduces latency to feed 
(Wang et al., 2008).  Consistent with our previous findings, we detected an overall 
postnatal treatment effect. In terms of adult FLX response, in control mice, adult chronic 
FLX treatment significantly reduced the latency to feed (Figure 3-4; p=0.0156); in 
PNFLX mice, adult chronic FLX treatment increased the latency to feed. We also 





















Figure 3-2. Novelty-suppressed feeding test. (A) The latency to begin feeding is shown in 
seconds. (B) Weight loss is expressed as a percentage of free-feeding body weight. 
PNFLX treatment from P2-P11 increased the latency to feed when compared with control 
mice treated with VEH. n =19 to 32 mice per group. *, p<0.05; **, p<0.01; ***, p<0.001 





Figure 3-3. Shock escape paradigm. (A) Average latency to escape a foot shock shown in 
seconds. (B) Locomotor activity before shocks. n = 19 to 32 mice per group. PNFLX 
treatment from P2-P11 increased the latency to escape when compared with control mice 
treated with VEH. *, p<0.05; **, p<0.01; ***, p<0.001 compared with their respective 





Figure 3-4. PN-FLX mice display anxiogenic response to chronic adult FLX treatment. 5-
htt+/+ and 5-htt-/- mice (left), as well as PNVEH and PNFLX treated mice (right) were 
assessed in the novelty suppressed feeding test after chronic adult VEH or FLX treatment 
(10 mg/kg/day, 21 days, i.p.). 5-htt+/+ mice and control mice respond to chronic adult 
FLX treatment by reducing their latency to feed, and 5-htt-/- mice do not respond to 
chronic adult FLX treatment. PN-FLX display an anxiogenic response to adult chronic 
FLX treatment, which is indicative of fundamentally altered functional connectivity of 5-
HTergic neurons to their postsynaptic targets. N = 17-30 per group, *: p < 0.05, **: p < 
0.01. 







Figure 3-1S. PN-FLX treatment has no effect on anxiety measures in the open field. 
Behavior in the open field was recorded for 30 minutes and the percentage of distance 
traveled in the center portion of the open field relative to the total distance traveled was 
calculated. There is no difference in center activity among different treatment groups. 
 
Discussions 
         Our findings demonstrated that P2 to P11 constitutes the critical period during 
which blockade of SERT resulted in increased depression and anxiety behavior. PNFLX 
treatment from P2 to P11 results in abnormal depressive and anxiety like behaviors in 
adulthood, while FLX treatment from P12 to P21 or from P22 to P41 does not produce 
this behavior deficit. The critical time window during which increased serotonin tone 
results in increased anxiety behavior is at least contained within P2-P11 period. In 
addition, adult FLX treatment failed to rescue the abnormal affective behavior in PN-




            5-HTergic neurons are generated early in development on embryonic days (E) 10 
to E12 in the mouse, and extend during early postnatal period (Levitt and Rakic, 1982; 
Luque et al., 1998). The full maturation of the axon terminal network requires more time 
and is achieved after birth in rodents (Lidov and Molliver, 1982). In addition to 5-
HTergic neurons, a number of cells in the central and peripheral neuronal systems show a 
transient 5-HTergic phenotype during development (Lebrand et al., 1998). 5-HTT has 
transient expression in both serotonergic and non-sertonergic cell groups in early 
developmental period (Homberg et al., 2010).  5-HTT has broad expression during early 
developmental period not restricting to raphe regions. Previous experiment that analyzed 
expression of 5-HTT in P0-P21 mice showed that strong transient expression of 5-HTT 
was observed in the thalamic nuclei during the first two postnatal weeks. The highest 5-
HTT expression was observed between P0-P7 in regions such as cortex, hippocampus, 
and subiculum (Lebrand et al., 1996; Lebrand et al., 1998).  Recent genetic fate mapping 
studies more precisely showed that 5-HTT expression extends to non-serotonergic 
neurons, including thalamus, somatosensory cortex, the hippocampus (starting E14–E15), 
cingulated cortex (starting E14-E15) and the medial prefrontal cortex (starting P0). 5-
HTT expression in non-serotonergic neurons ends rapidly during the second postnatal 
week, coinciding with the maturation of neural circuits (Narboux-Neme et al., 2008). The 
critical time window of P2 to P11 that we determined is congruent with the period of 
transient serotonergic phenotype and 5-HTT expression.  
            The 5-HT sensitive period described here coincides with the onset of anxiety and 
depression- related behaviors and the development of the underlying brain structure and 




switches from preference to aversion, with amygdala engagement and hypothalamic-
pituitary-adrenal axis integration. P2 to P11 is a critical period of synaptogenesis, axon 
growth and dendrite development (Pokorny and Yamamoto, 1981; Bahr and Wolff, 1985; 
Innocenti and Price, 2005). The cortical brain structure during this period is undergoing 
rapid changes in morphology and volume (Zhang et al., 2006). Hippocampus 
development takes place during post-natal period in rodents, with a critical maturation 
period coinciding with the time that serotonergic neuronal innervation occurs (Swann et 
al., 1989; Tansey et al., 2002; Gaspar et al., 2003). It is likely that the early-life 
dysregulation of serotonergic tone in PN-FLX mice would impact the proper 
development of many brain structures and cause permanent physiological, structural, and 
behavioral changes in adulthood. 
             Developmental disruption of serotonin system in mice has been shown to result 
in changes in serotonergic system as well as other critical structures. For instance, 
postnatal citalopram treatment from P8 to P21 can lead to a reduction in the density of 5-
HTT immunoreactive (-ir) fibers in cortex (Maciag et al., 2006) and abnormal callosal 
connectivity and distorted activity profile of cortical neurons in primary auditory cortex 
when examined after treatment period (Simpson et al., 2011); postnatal treatment with 
SSRIs can lead to up-regulation of BDNF mRNA in the hippocampus (Karpova et al., 
2009). PN-FLX treatment results in a decreased dendritic arborization of serotonergic 
fibers in the infralimbic (IL) sub-region of the mPFC, retraction of dendritic arbors in 
CA3 regions of the hippocampus, and reduced total spine number and density of CA3 
neurons (unpublished data Tahilia Rebello). Administration of 5-HT1A  agonist 




the loss of dendritic spines, and administration of 5-HT1A antagonist (NAN-190) to naive 
pups from P3 to P14 produced a reduction in the number of dendritic spines and total 
dendritic length (Yan et al., 1997). Therefore, the brain structures and circuitry implicated 
in affective disorders might be permanently changed in a manner that contributes to the 
altered adult anxiety and depression behavior in adulthood.       
            Additionally, low-expression 5-htt allele has been associated with neuroticism, 
anxiety and depression state in humans (Lesch et al., 1996; Sen et al., 2004). Our PNFLX 
animal model captured the behavioral aspects as shown in anxiety and depression related 
measures. Human “s” allele carriers exhibit diminished functional connectivity between 
the mPFC and the amygdale, in response to fearful stimuli in functional magnetic 
resonance imaging (fMRI) studies (Heinz et al., 2005; Pezawas et al., 2005). Moreover, 
there is reduced gray matter volume in short-allele carriers within the prefrontal cortical 
regions (Pezawas et al., 2005). This PNFLX animal model also exhibits morphological 
and physiological changes in these relevant brain regions in adulthood. Our PNFLX 
model serves a useful purpose for future study on the etiology and pathogenesis of 
depression and anxiety related disorders. This study also suggests that low-expressing 
allele may act during very early neonatal period to modify brain circuits that predisposes 
the carriers of these alleles to emotional disorders later in adult.  
            The SSRIs are used as a first-line treatment for psychiatric conditions such as 
major depression, generalized anxiety disorder, panic disorder, and obsessive-compulsive 
disorder. These agents are being used to treat these conditions in children and pregnant 
women, with 25% of depressed women continuing using anti-depressants throughout the 




period is a growing health concern that could affect up to 20% of women (Leung and 
Kaplan, 2009; Marcus, 2009). The current widespread use of SSRIs during pregnancy 
and childhood without knowing their long-term effects clearly constitutes an important 
public health concern. Our experiment in mice provides evidence on assessing the risk of 
antidepressants in pregnant woman. Since the P2-P11 period in rodents corresponds to 
human third trimester (Romijn et al., 1991), our experiment poses important health 
considerations for clinicians prescribing medicine to pregnant women with depression 
and anxiety disorders.  
            Currently up to 50% depression patients don’t respond to SSRIs. The serotonin 
transporter gene encodes a direct molecular target of SSRIs. 5-htt genetic variant is 
associated with response to antidepressants. Human studies have shown that there exists a 
significant interaction of the low expression polymorphism and poor drug response 
(Lohoff; Smeraldi et al., 1998; Pollock et al., 2000; Murphy et al., 2004b; Lotrich and 
Pollock, 2005; Serretti et al., 2007; Wilkie et al., 2009). Animal studies in 5-htt knockout 
mice have shown that deletion of 5-htt gene renders the animals insensitive to the 
behavior effects of fluoxetine treatment (Holmes et al., 2002b). This thesis research 
shows early life 5-HTT blockade produces increased anxiety and depression like 
behaviors, which cannot be reversed by adult SSRI treatment. This finding provides a 
possible developmental explanation of the SSRI non-responders in depression patients. 
Inhibition of 5-HTT activity or excessive serotonin activity during development could be 
a risk factor for both etiology of affective disorders and poor treatment response to 5-














            5-HT exerts its functions via 5-HT receptors and their downstream signaling 
pathways. These receptor subtypes have a central role in affective states and 
physiological functions. Among all the receptors, 5-HT2A receptors have been implicated 
in the etiology and treatment of various psychiatric disorders. hrt2a -/- mice have shown 
increased anxiety phenotype (Weisstaub et al., 2006). 5-HT2A receptor is also implicated 
in treatment of anxiety disorders and response to antidepressants (Carson and Kitagawa, 
2004; McMahon et al., 2006; Millan, 2006; Aloyo et al., 2009).  
            Serotonin induces differential effects in rat layer V pyramidal neurons during 
different postnatal periods (Beique et al., 2004b; Beique et al., 2004a). Serotonin induced 
excitatory response in the first two postnatal weeks and inhibitory responses after P20 in 
rat layer V pyramidal neurons. This effect is due to a shift from 5-HT2A receptor to 5-
HT1A receptor, with 5-HT2A receptor mediating the depolarization effect and 5-HT1A 
receptor mediating the hyper-polarization response (Zhang, 2003; Beique et al., 2004b).  
            Increased serotonin signaling from P2-P11 leads to increased anxiety- and 
depression- like behaviors in adulthood. This developmental period (P2-P11) is 
congruent with the time window that serotonin induces excitatory response via 5-HT2A 
receptor. Moreover, pharmacological blockade of 5-HT1A receptor from P13 to P34 is 
sufficient to produce the anxiety- and depression- like phenotype in adulthood (Lo Iacono 




mediated inhibitory response, which indicates that P13-P34 a critical time for 5-HT1A 
mediated serotonin signaling. It is likely that developmental 5-HT signaling during P2-
P11 period exerts its effect via 5-HT2A receptor impacting adult behaviors. Taken 
together, this leads to the hypothesis that early postnatal 5-HT2A receptor signaling 
mediates effects of developmetnal 5-HT signaling during P2-P11 period. Thus we tested 
the effect of postnatal FLX treatment on adult anxiety and depression- like behaviors by 
using htr2a -/- and htr2a +/+ mice. 
 
Figure 4-1 The critical period model. [Based on (Beique et al., 2004b; Weisstaub et al., 
2006; Lo Iacono and Gross, 2008)] 





            Pups were injected intraperitoneally daily (2:00 pm -5:00 pm) with either vehicle 
(0.9% NaCl, 5ml/kg) or Fluoxetine (10 mg/kg, 5ml/kg) starting on postnatal day (P2) 
until P11. Mice were treated once per day for all these experiments. For treatment, entire 
litters were removed from dams and placed into a petri dish (10 cm diameter) containing 
shavings from the respective home cage. The petri dish was resting on scales, to allow for 
weighing mice after picking them up. Mice were injected in random order, and an entire 
litter was injected within 2 min. Immediately after injection, mice were placed back into 
the home cage. Mice were weaned after P22. Mice were genotyped using PCR of 
genomic DNA isolated from tissue samples following established protocols (Weisstaub et 
al., 2006). Animals were separated by sex and group housed with both WT and Knockout 
mice present in each cage. 
             The animals for behavior testing are bred via 5-ht2A +/- breeders. htr2a -/- mice 
were generated as described previously (Weisstaub et al., 2006). Animals carrying 
htr2a+/-mutation were intercrossed to obtain a mix of wild type (htr2a+/+), 
heterozygous (htr2a+/-), and knockout (htr2a-/-) offspring. The animals used for in-situ 
hybridization are WT animals. Animals were maintained on a 12-hour light-dark cycle 
(lights on at 8am) and provided with food and water. Animal testing was conducted in 
accordance with the Principles of Laboratory Animal Care National Institute of Health 
(NIH) guidelines and the institutional animal committee guidelines.  
 
Drugs 
            For the studies involving postnatal drug administrations, fluoxetine (ANAWA 




concentrations: fluoxetine, 2 mg/ml. Solutions were prepared fresh every day.  
 
Behavior Testing 
We used the same protocols as in chapter II.  
 
In situ hybridization  
 In situ hybridization were performed on 15–20 µm cryostat sections as described 
(Demireva et al.).  In brief, on the first day, prepare slides, add Hybridization Solution on 
each slide, incubate from 1hr to 6hrs at room temperature. On the second day replace pre-
hyb solution with 100ul of hybrydization solution containing the probe (100ug/ul), cover 
slip slides carefully, place in sealed humidified black boxes and incubate in 72ºC 
incubator. Remove slides, wash slides in buffers, replace with anti-DIG Ab solutions 
(dilute AP-conjugated sheep anti-DIG Ab 1:5000, Roche #  1 093 274, in Buffer B2) and 
incubate slides with Ab at 4ºC in a humidified chamber. When signal is developed 
enough, stop reaction and mount slides.  
 
Data analysis 
            Statistical analysis was performed using StatView 5.0 software (SAS Institute). 
Data were analyzed using Student's t test or one- or two-way ANOVA. The criterion for 
significance for all analyses was p < 0.05. Results from data analyses are expressed as 






Developmental expression of 5-ht2a receptor in prefrontal cortex 
            PNFLX treatment has caused physiological and anatomical changes in prefrontal 
cortex area such as reduced dendritic arborazation in the layer 2/3 pyramidal neurons in 
the IL of mPFC areas as well as changes in electrophysiological properties of the IL and 
PL pyramidal neurons (unpublished data Tahilia Rebello). In addition, the anxiety 
phenotype of htr2a -/- mice can be normalized by cortical 2A receptor re-expression.  
Thus we hypothesis cortical 5-HT2A receptor might be critical for the increased 5-HT 
signaling during early developmental period. First, we performed in situ hybridization 
experiment at P8 and adulthood in prefrontal cortex area to examine 5-HT2A receptor 
expression pattern in cortical areas. We observed that 5-HT2A receptor has strong 
expression in frontal cortex (obital cortex, mPFC) at P8. In adulthood 5-HT2A  receptor 






Figure 4-2 Representative pictures examining 5-HT2A receptor expression in prefrontal 
cortical areas. The upper panel is coronal sections at P8; The lower panel is coronal 
sections at adulthood P137. Obtained from Elena Demireva 
 
The effect of PN-FLX on exploratory activity in novel environment  
            To test whether 5-HT2A mediated the PN-FLX effect on adult emotional behavior, 
we compared the effect of PN-FLX on htr2a  +/+ and htr2a -/- mice. These mice were 
generated from crossing of htr2a+/- mice to obtain a mix of wild type (htr2a+/+), 
heterozygous (htr2a+/-), and knockout (htr2a-/-) offspring. The offspring is the mice that 
are undergoing PN-FLX treatment and behavior testing. We first tested mice in the open 
field. We detected an overall treatment effect in total distance traveled and vertical 
activity; we did not detect an interaction of genotype and treatment. In comparison to 
vehicle-treated groups, PN-FLX treatment decreased exploratory behavior significantly 




ambulatory time (Figure 4-3B; ANOVA p=0.0078) and vertical activity (Figure 4-3C; 
ANOVA p=0.0163). The results indicate that the effects of PN-FLX in exploratory 
activity were not mediated by 5- HT2A receptor.  
 
The effect of PN-FLX treatment in test sensitive to chronic antidepressant treatment 
            To decide whether 5-HT2A receptor mediates the postnatal FLX effects on conflict 
anxiety behavior, we examined the effect of postnatal FLX treatment in novelty-
suppressed feeding paradigm. In the NSF, food-deprived mice are presented with a 
familiar food pellet in a novel, brightly lit environment and the latency to approach the 
food and begin a feeding bout is recorded. We detected the genotype and postnatal 
treatment interaction (ANOVA p=0.0076). The results showed that PN-FLX treatment 
from P2 to P11 increased the latency to feed in WT mice compared with VEH-treated 
mice (Figure 4-4A; p=0.0251); while PN-FLX treatment does not produce this behavior 
deficit in 5-HT2A +/- or 5-HT2A -/-mice. In terms of percentage of weight loss, no 
treatment effect was detected (Figure 4-4B). 
 
The effect of PN-FLX treatment on behavioral stress response  
            We also examined the effects of PN-FLX in shock escape, a paradigm that 
assesses behavioral responses to stress. We detected the overall treatment effect 
(ANOVA p=0.0001). We did not detect any postnatal treatment and genotype interaction. 
The results showed that PN-FLX treatment significantly increased the latency to escape 




effect in pre-shock activity (Figure 4-5B). This indicates that the effect of FLX in shock 
escape paradigm is not mediated by 5-HT2A receptor.  
            In summary these results indicate that 5-HT2A receptor mediate PN-FLX response 
in conflict anxiety behavior paradigms. In exploratory behavior and shock escape 





Figure 4-3. Exploratory behavior in the open field. In the open field, the following 
parameters were scored for 30minutes:  total distance traveled (A), ambulatory time (B), 
and vertical activity(C). PNFLX treatment reduced ambulating time, distance, and rear 
activity in all three genotype groups. *, p<0.05; **, p<0.01; ***, p<0.001 compared with 





Figure 4-4. Novelty-suppressed feeding test. (A) The latency to begin feeding is shown in 
seconds. (B) Weight loss is expressed as a percentage of free-feeding body weight. FLX 




FLX treatment did not exhibit such effect in 5-HT2A KO mice in comparison to VEH 
treated mice. n = 15-20 mice per group. *, p<0.05 compared with their respective 





Figure 4-5. Shock escape paradigm. (A) average latency to escape a foot shock shown in 
seconds. (B) Locomotor activity before shocks. n = 15-20 mice per group. PNFLX 
increased latency to escape in all three genotype group in comparison to PNVEH controls. 
No treatment and genotype interaction was detected. Treatment dose not have effect on 
preshock locomotor activity. ***, p<0.001 compared with their PN-VEH controls. VEH, 








             This research shows that 5-HT2A receptor is highly expressed in prefrontal areas 
during development as well as in adulthood. We find that blockade of 5-HT2A receptor is 
sufficient to rescue some aspects (novelty suppressed feeding behavior in NSF test), but 
not all aspects of anxiety and depression-like behaviors (no change in helplessness 
behavior in SE test, no changes in exploratory behaviors in open filed). Our findings open 
new insights into the developmental mechanisms linking 5-HT2A receptor with early life 
5-HTT manipulations on adult emotional behavior.  
            The 5-HT2A receptor is one of the most widely expressed 5-HT receptors in the 
brain. Several studies have indicated that 5-HT2A receptors are important in neuronal 
differentiation and dendritic maturation (Lavdas et al., 1997; Azmitia, 2001). 5-HT2A 
receptor is highly expressed during early postnatal period as demonstrated by previous 
studies (Roth et al., 1991; Volgin et al., 2003) and our own experiments, which 
implicates its involvement in the developmental etiology of anxiety/depression. Ablation 
of this receptor could potentially affect the whole serotonin system and this receptor 
mediated intracellular pathways, which could exert influence on physiology and 
behaviors.    
            Our experiment using htr2a -/- mice investigated the influence of 5-HT2A receptor 
on adult affective behavior elicited by postnatal 5-HTT blockage. PN-FLX exerts no 
effect in 5-HT2A -/- mice, while PN-FLX increased latency to feed in WT mice. This 
result suggests that PN-FLX exerts its effect through 5-HT2A receptor in this anxiety 




factorial, multi-symptom heterogeneous disorder, it is unlikely that one behavior model 
of antidepressant action will encompass all aspects of this disease (Schmidt and Duman, 
2007). Novelty-suppressed feeding (NSF) test is a conflict anxiety test that responds to 
chronic but not acute or subchronic, antidepressant treatments as well as to anxiolytic 
medications (Santarelli et al., 2003; Dulawa et al., 2004). Our own experiment in the lab 
has demonstrated that IL leisions in the mPFC could result in deficit in NSF test in 
comparison to controls, which implicates mPFC is a critical area for aspects of depression 
and anxiety disorders reflected in NSF test (unpublished data Tahilia Rebello). 5-HT2A 
receptor has very strong expression in the frontal cortex. Electrophysiological studies also 
suggest that serotonin induced depolarization effect in the pyramidal neurons of the 
cortex are mediated by 5-HT2A receptor during the first two postnatal weeks development 
(Beique et al., 2004b; Beique et al., 2004a). PN-FLX treatment will result in increased 
serotonergic tone; it is probable that concurrently deactivating the 5-HT2A receptor in this 
developmental period could ameliorate this influence of increased serotonin tone on the 
maturation of brain structures such as mPFC or physiological functions. Additionally, it 
is noted that abolishment of hippocampus neurogenesis by X-ray of hippocampus 
suppresses behavioral responses to antidepressants in NSF test (Santarelli et al., 2003). 
Hippocampus lesions, particularly ventral hippocampus lesions, result in altered anxiety-
like behaviors such as reduced hyponeophagia (Bannerman et al., 2002; Bannerman et al., 
2003). 5-HT2A receptor also has strong expression in hippocampus CA3 region (data not 
shown). Early-life exposure to FLX results in a retraction of the apical dendritic arbor in 
the CA3 hippocampus area and reduced spine number and spine density in the 




HT2A receptor might also mediate the increased 5-HT signaling on anxiety measures. 
Taken together, it is probable that blockade of 5-HT2A signaling counteracts the increased 
serotonin signaling during this early developmental (P2-P11) period, which leads to 
normalized behavior in this conflict anxiety behavior model.  
            In the open field and shock avoidance paradigm, PN-FLX has an overall effect on 
adult behaviors, and we did not detect genotype and treatment interaction. Open field test 
is a classical approach/avoidance paradigm in which the novel environment concurrently 
evokes both anxiety and exploration (Prut and Belzung, 2003). Shock avoidance 
paradigm reflects an innate helplessness. The results reflect that 5-HT2A receptor 
deactivation is not mediating PN-FLX effect on exploration behavior and helpless 
behavior in adulthood. The fact that the ablation of 5-HT2A receptor is not sufficient to 
normalize the exploratory behavior or helpless behavior deficit suggest that other 
receptors or neurotrophic factors or other developmental events, which are impacted by 
excessive 5-HT signaling during this early development, contribute to the altered 
emotional phenotype in open field and shock avoidance paradigm.  
 
Considerations and remarks 
            Here in this study we use constitutive KO mice to investigate the developmental 
mechanisms by which early life 5-HTT blockade affects adult anxiety-and depression-
related behaviors. Thus, it is unavoidable that some compensatory mechanisms might 
intervene the interpretation of the results. For future work, it is desirable to have a 
transgenic mouse line that could turn on or turn off 5-HT2A expression in a tissue-specific 




            Although we have shown 5-HT2A receptor reverse some aspects of anxiety-and 
depression-like behaviors produced by early life 5-HTT blockade, the detailed 
mechanisms on how this affects specific intracellular signaling pathways and how this 
mediate the effects of serotonin on dendritic morphology and ultimately behavior, require 
further characterization.  
            In addition, other receptors, circuitry, transcription factors or a variety of 
molecules might be involved in the innate helpless behavior. The neurotrophin family 
including BDNF, NGF, and neurotrophin-3 et al plays very important roles in the 
development, differentiation, maintenance, and survival of neuronal populations in the 
nervous system (Levi-Montalcini, 1987; Barde, 1989). Chronic fluoxetine treatment can 
up-regulate BDNF mRNA in hippocampus (Nibuya et al., 1995; Nibuya et al., 1996). It is 
likely that the enhancement of neurotrophic factors will lead to normalized behaviors.  
GABAergic inter neurons, or glutamate transmission might be involved in the aspects of 
anxiety- and depression- like behaviors. The net effect of the excitatory vs inhibitory 
input/output might regulate the effect of excessive 5-HT signaling on various maturation 
process including neuronal proliferation, migration, arborization, and integration 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix A  The role of 5-HT7 receptor in adult antidepressant related behavioral 
response and adult neurogenesis 
Introduction  
             SSRIs are the first line medicine for depression and anxiety disorders. SSRIs 
influence serotonin system to ameliorate symptoms of depression (Kent, 2000). However, 
SSRIs typically require chronic administration to produce beneficial effects in humans, 
suggesting that events downstream of serotonin signaling are ultimately altering 
behavior/emotion.  
         Structrual and functional changes associated with chronic SSRI treatments have 
been identified, however, there is lack of established causal relationship between these 
changes.  The amounts of hippocampal camp response element binding protein (CREB) 
and adult hippocampal neurogenesis are both increased after chronic SSRI treatment. In 
addition, the causal relationship has been established. Blocking adult hippocampal 
neurogenesis (through focal irradiation or genetic ablation) abolishes the effects of SSRIs 
on anxiety and depression-like behaviors in rodents. Pharmacologically elevated cAMP 
signaling increases proliferation of progenitors and survival and maturation of adult born 
dentate gyrus neurons through CREB activation. Furthermore, dominant negative CREB 
expressed exclusively in newly generated cells reduces neuronal survival and impairs 
maturation (Merz et al).  
            Different receptors in serotonin system have been found to regulate anxiety and 
depression behavior. Activation of the adenylate cyclase pathway induces CREB (refs). 
Among 14+ 5-HT receptors which have been cloned and characterized thus far, only the 




cortex and the CA1, CA2, CA3 and dentate gyrus subfields of the hippocampus, and thus 
well positioned to impact neurogenesis through CREB signaling in a non cell-
autonomous fashion (Bonaventure et al., 2002; Hedlund and Sutcliffe, 2004; Kvachnina 
et al., 2005). Furthermore, htr7 is expressed in newly born cells that proceed towards 
neuronal differentiation (personal communication Grigori Enikolopov), theoretically 
allowing for modulation of cell survival and maturation through CREB signaling. We 
hypothesized that 5-HT7 receptor mediates the consequences of chronic SSRI treatment 
on CREB induction, neurogenesis activation and anxiety and depression behavior. Based 
on this information, we sought to investigate the involvement of the 5-HT7 receptor in the 
cascade of events following chronic SSRI administration and the resulting reduced 
anxiety and depression-like behavior. 
 
Materials and Methods 
Animals  
            Mice were housed five per cage in a 12 h light/dark colony room at 22°C with 
available food and water. All experiments were performed in compliance with the 
institutional regulations and guidelines for animal experimentation. Mice were injected 
subcutaneously with fluoxetine (10mg/kg) daily for 4 weeks.  
 
Immunohistochemistry and imaging.  
            Mice were anesthetized with ketamine/xylazine (100 and 7 mg/kg, respectively) 
and transcardially perfused (cold saline, followed by 4% cold paraformaldehyde in PBS). 




30% sucrose, and stored at 4°C. Serial sections were cut through the entire hippocampus 
using a cryostat and stored in PBS. Immunohistochemistry was performed in the 
following steps: For BrdU staining, euqilibrate with PBS containing 0.1% triton X/100 
for 30 min; 30 min incubation in 2N HCl at room temperature, and 3×10 min rinse in 
PBS; 1 hr incubation in 0.1 M PBS with 0.1% Triton X-100, and 3% normal donkey 
serum. Sections were then incubated overnight at 4°C in primary antibodies for 
bromodeoxyuridine (BrdU; mouse; 1:100; Serotec, Oxford, UK). Biotinylated secondary 
antibodies were used. All secondary antibodies were purchased from Jackson 
ImmunoResearch (West Grove, PA). DCX staining was done as follows: sections were 
rinsed in PBS, treated with 0.3% H2O2 in PBS for 30 min to quench endogenous 
peroxidase activity (and to enhance dendritic staining), incubated in 0.1M PBS with 5% 
normal donkey serum and 0.5% Triton X-100 for 1 hr, and then incubated overnight at 
4°C in primary antibody for doublecortin (goat; 1:500; Santa Cruz Biotechnology, Santa 
Cruz, CA). After secondary antibody incubation, sections were developed using Vector 
ABC kit and DAB kit. Stereological procedure was used to quantify labeled cells 
(Malberg et al., 2000). 
 
Western blot 
            Brain tissues are prepared as followings: brains are dissected and put into 
Eppendorf tubes; tissues are added lysis buffer which is composed of 0.2M NaCl, 5nM 
EDTA, Glycerol 10%, NaPPi 2mM, HEPES 100mM, protease inhibitor cocktail, 
phosphotase inhibitor I &II cocktail, PMSF (0.5mM), NaF (2mM); homogenize tissue in 




14000rpm to get supernatant A; transfer supernatant A to new set tubes on ice; repeat the 
last step; store sample at -80 degrees. Concentrations of final sample are measured using 
Pierce BCA Protein Assay Kit (Fisher Scientific). Western blot are done in the following 
steps: prepare the transfer buffer; add 2×loading buffer (Tris-Cl pH=6.8 100mM; SDS 
4%; BPB 0.2%; Glycerol 20%; DTT 200nM); prepare a tube with molecular weight 
marker; boil samples in loading buffer for 5 mins at 100 degrees and spin them down; 
prepare running buffer (Trizma-base 25mM; Glycine 192mM; SDS 5.0g); run the gel 
first at a low voltage (~90V) until the dye is through the stacking gel and then it can be 
increased to 130-150V when samples are in the separating gel; set up the transfer 
equipment; run the transfer for 1 hr at constant 100V and 0.35 Amp; after 1 hr, dissemble 
the transfer sandwiches and place the membranes protein side up in tray and wash in 
water 2 x 30 sec; block membranes for 1 hr – 5% milk in TBS-T; incubate membranes in 
primary antibody overnight; pour off Primary Antibody solution; wash membrane 3 x 10 
min in TBS-T at room temperature; add 1:5000 secondary antibody; wash membrane 3 x 
10 min; develop the membrane using ECL kit (GE Healthscience). 
 
Novelty-induced hypophagia test 
            Mice were trained to drink sweetened condensed milk for three consecutive days. 
Mice were presented with diluted (1:3; milk:water) sweetened condensed milk 
(Carnation) for 1 hour each day. Milk was presented in 10 ml serological pipettes with 
sippers attached with parafilm. Pipettes were closed with rubber stoppers and positioned 
through wire cage lids. Novel cage testing occurred when mice were placed into new 




sweetened condensed milk after training days. The latency to start drinking and the 
amount consumed over a 30 min interval was recorded. On the following day, mice were 
presented a pipet with sweetened condensed milk in their homecage, and the latency to 
start drinking and the amount consumed over a 30 min interval was recorded. The latency 
to drink, and the volume consumed were recorded every 5 min for 30 min.  
 
Novelty-suppressed feeding test  
Refer to chapter II 
 
Statistic analysis 
            Statistical analysis was performed using StatView 5.0 software (SAS Institute, 
Cary, NC). Data were analyzed using Student’s t test, or two-way ANOVA with Student–
Newman–Keuls posthoc testing; survival analysis, Kaplan-Meier, Logrank Mantel-Cox 
test as indicated. The criterion for significance for all analyses was p < 0.05. Results from 
data analyses are expressed as mean ± SEM. 
  
Results 
5-HT7 receptors are necessary for SSRIs to induce CREB in the hippocampus. 
            Chronic SSRI treatment has been shown to increase CREB expression (Nibuya et 
al., 1996). 5-HT7 receptors couple to Gs and activation of the adenylate cyclase pathway 
induces CREB phosphorylation and creb expression (Meyer et al., 1993; Widnell et al., 
1994). Thus, 5-HT7 receptor activation has been hypothesized to mediate the effects of 




            To test this hypothesis we administered the SSRI fluoxetine (FLX, 10 mg/kg/day, 
drinking water) or vehicle (VEH) for 21 days to htr7+/+ and htr7-/- littermates and 
assessed CREB and GAPDH protein abundances in the hippocampus (HIP) using 
western blot analysis (Figure 2). We detected a significant interaction between genotype 
for CREB/GAPDH levels in the HIP (F(1,27)=; p=0.0060). Post-hoc analysis revealed that 
FLX increases CREB/GAPDH levels in the HIP of htr7+/+ mice (F(1,18)=8.884, 
p=0.0284). Conversely, FLX decreased CREB/GAPDH levels in the HIP of htr7-/- mice. 
In terms of pCREB levels, we detected a significant interaction between genotype and 
treatment for pCREB/GAPDH levels in the HIP (F(1,27)=8.723, p=0.0064). Post-hoc 
analysis revealed that FLX dose not change pCREB/GAPDH levels in the HIP of htr7 
+/+ mice, but decreases pCREB/GAPDH levels in the HIP of htr7-/- mice (F(1,9)=15.227, 
p=0.0036). Taken together, these findings demonstrate that 5-HT7 receptor signaling is a 
necessary component for chronic FLX treatment to increase CREB levels in HIP and to 






Figure A-1 5-HT7 receptor is necessary for SSRIs to induce CREB in the hippocampus. 
A) Representative picture of western blot of acute fluoxetine (FLX) treatment on CREB 
and pCREB levels. B) Acute FLX significantly increased CREB levels in htr7+/+ mice 
while not in 5-htr7-/- mice in comparison to controls. C) Acute FLX significantly 
increased pCREB levels in htr7+/+ mice while not in 5-htr7-/- mice in comparison to 
controls. D) Representative picture of western blot of chronic fluoxetine (FLX) treatment 
on CREB and pCREB levels. E) Chronic FLX significantly increased CREB levels in 
htr7+/+ mice while reduced CREB levels in 5-htr7-/- mice compared with VEH controls. 
F) Chronic FLX did not change pCREB levels in htr7 +/+ mice while reduced pCREB 
levels in htr7 -/- mice in comparison to controls. n=4-7  
 
5-HT7 receptors are not necessary for SSRIs to induce neurogenesis. 
            We next investigated if the effects of chronic SSRI treatment on proliferation of 




signaling. Based on the established link between CREB signaling and adult hippocampal 
neurogenesis, we hypothesized that htr7-/- mice would have a blunted neurogenic 
response to chronic FLX treatment. 
            Htr7+/+ and htr7-/- mice were treated with chronic FLX (10 mg/kg/day, i.p.) or 
VEH for 21 days. On day 21, mice were injected with BrdU (150 mg/kg) and sacked 2h 
later. BrdU incorporation in the hippocampus was assessed using immunohistochemistry. 
We detected a main effect of FLX treatment (F(1, 15)=15.380, p= 0.0014) and no effect of 
genotype or treatment X genotype (F(1, 15)=0.295, p=0.5951; F(1, 15)=0.128, p=0.7254 
respectively) on BrdU-positive cells (Figure A-2A). Likewise, we detected a main effect 
of FLX treatment (F(1,15)=13.108, p=0.0025) and no effect of genotype or treatment X 
genotype (F(1,15)=0.074, p=0.7892; F(1,15)=0.013, p=0.9096) on BrdU-positive cell-
clusters (Figure A-2B). No differential effect of FLX in htr7+/+ versus htr7-/- mice was 
detected for either measure (Figure A-2B). 
            Doublecortin (DCX) is a marker of young neurons and is expressed in young 
neurons at 2-3 weeks of age (Couillard-Despres et al., 2005). Chronic SSRI treatment 
increases the amount of DCX-positive cells in the DG (Wang et al., 2008). To assess if 
SSRI treatment increases the amount of DCX positive cells in the DG through 5-HT7 
receptor signaling, we treated htr7+/+ and htr7-/- mice with chronic FLX (10 mg/kg/day, 
drinking water) or VEH for 21 days. On day 21, mice were sacked and brains were 
stained for DCX. DCX positive cells in the hippocampus were quantified using 
stereology. We detected a main effect of FLX treatment (F(1,14)=0.0075, p=0.0075) and 




p=0.6904 respectively) on DCX-positive cells (Figure A-2C). No differential effect of 
FLX in htr7+/+ versus htr7-/- mice was detected (Figure A-2C). 
            During the DCX-positive period, neurons undergo morphological maturation. One 
maturation indicator sensitive to chronic SSRI treatment is the dendritic tree complexity. 
Specifically, chronic SSRI treatment increases the number of DCX-positive neurons with 
tertiary dendrites. To assess if SSRI treatment increases the amount of DCX-positive 
cells with tertiary dendrites in the DG through 5-HT7 receptor signaling, we quantified 
DCX positive cells with tertiary dendrites in the hippocampus of htr7+/+ and htr7-/- mice 
treated with chronic FLX (10 mg/kg/day, drinking water) or VEH for 21 days using 
stereology. We detected a main effect of FLX treatment (F(1,14)=7.807, p=0.0109) and no 
effect of genotype or treatment X genotype (F(1,14)=0.085, p=0.7731; F(1,14)=0.411, 
p=0.5283) on DCX-positive cells with tertiary dendrites (Figure A-2D). No differential 
effect of FLX in htr7+/+ versus htr7-/- mice was detected (Figure A-2). 
            Taken together, our data demonstrate that 5-HT7 receptor signaling is not 
necessary for SSRIs to increase proliferation of DG progenitor cells and maturation of 










Figure A-2. 5-HT7 receptors are not necessary for SSRIs to induce neurogenesis. A), B) 
Chronic FLX treatment increases the number of BrdU positive cells or cell clusters 
compared with VEH treated mice in 5-htr7 +/+ and 5-htr7 -/- mice. C) Chronic FLX 
treatment increases the number of DCX positive cells in 5-htr7-/- mice, and dose not 
change the number of DCX positive cells in 5-htr7 +/+ mice. D) Chronic FLX treatment 
increases the number of DCX positive cells with tertiary dendrites in 5-htr7 +/+ and 5-
htr7 -/- mice. n=4-6 mice.  
 
 
5-HT7 receptor is not necessary for SSRIs to reduce anxiety and depression-like behavior. 
            We next investigated if the effects of chronic SSRI treatment on behavior depend 
on 5-HT7 receptor signaling. Behavior was assessed in three tests with predictive validity 
for chronic SSRI treatment: the NSF test and the novelty induced hypophagia test (NIH).  
            We treated htr7+/+ and htr7-/- mice with FLX (10 mg/kg/day, i.p.) for 21 days 
and then sequentially assessed behavior in the NSF and NIH. Behavioral tests were 
spaced by one week while FLX treatment continued. For the NSF, mice were food 




start feeding in a novel arena, and homecage food consumption. In the NSF, the latency 
to start feeding is sensitive to chronic SSRI treatment (Wang et al., 2008). We detected 
main effects of treatment and genotype but no treatment X genotype interaction for the 
latency to start feeding (F(1,88) = 5.779, P = 0.0183; F(1,88)= 11.332, P = 0.0011 and F(1,88) 
= 0.020, P = 0.8883 respectively) (Figure A-3). Posthoc analysis revealed that chronic 
FLX treatment reduced the latency to feed while htr7 ablation increased the latency to 
feed (Figure A-3). No effect of treatment or genotype and no treatment x genotype 
interaction was detected for body weight reduction (F(1,88) = 3.041, P = 0.0847; F(1,88)= 
2.959, P = 0.0889 and F(1,88) = 0.097, P = 0.7562 respectively) or homecage food 
consumption (F(1,88) = 1.479, P = 2.271; F(1,88)= 1.077, P = 0.3023 and F(1,88) = 3.158, P = 
0.0790 respectively) (Figure A-3). 
            For the NIH test, mice were first trained to drink sweetened condensed milk from 
a pipet. Subsequently, mice were placed into a novel environment having a pipet filled 
with sweetened condensed milk available. The latency to start drinking and the amount 
consumed over a 30 min interval was recorded. On the following day, mice were 
presented a pipet with sweetened condensed milk in their homecage, and the latency to 
start drinking and the amount consumed over a 30 min interval was recorded. In the NIH, 
the latency to start drinking in a novel environment and the % inhibition of sweetened 
condensed milk consumption are sensitive to chronic SSRI treatment (Dulawa and Hen, 
2005). We detected main effects of treatment (p=0.0113) but no genotype or treatment X 
genotype interaction for the latency to start drinking (Figure A-4B, C). Posthoc analysis 
revealed that chronic FLX treatment reduced the latency to drink (Figure A-4B, C). We 




for the % inhibition (F(1,61) = 5.239, P = 0.0256; F(1,61) = 9.806, P = 0.0027; and F(1,61) = 
0.027, P = 0.8689, respectively ) (Figure A-4A). Posthoc analysis revealed that chronic 
FLX treatment and htr7 ablation both reduced novelty induced inhibition of sweetened 
condensed milk consumption (Figure A-4A). 
            Taken together, htr7-/- mice are fully sensitive to chronic SSRI treatment in 
multiple tests assessing anxiety and depression-like behavior. 
 
Figure A-3 Chronic SSRIs reduce latency to feed in novelty suppressed feeding test. (A), 
(B) Chronic FLX treatment reduced latency to feed in 5-htr7 +/+ and 5-htr7 -/- mice. No 
effect of treatment or genotype and no treatment x genotype interaction was detected for 
body weight reduction (C) and home cage food consumption (D). VEH, vehicle; FLX, 





Figure A-4 Chronic SSRIs reduce anxiety-and depression-related behavior in novelty 
induced hypophasia test. (A) Chronic FLX treatment reduced the inhibition in 5-htr7 +/+ 
and 5-htr7 -/- mice. (B), (C) Chronic FLX treatment reduced the latency to feed in novel 
cage in 5-htr7 +/+ and 5-htr7 -/- mice. VEH, vehicle; FLX, fluoxetine. *p<0.05 
 
Discussion 
            In the present study, we have demonstrated that chronic fluoxetine increases 
proliferation of immature neurons in the DG of hippocampus independent of 5-HT7 
receptor. We also demonstrate that 5-HT7 receptor signaling is a necessary component for 
chronic FLX treatment to increase CREB levels in the hippocampus and to keep stable 
levels of pCREB levels in hippocampus, supporting the hypothesis that 5-HT7 receptor 
mediates the effect of chronic antidepressants on transcription factor CREB. In assessing 
the behavioral consequences of the physiological actions of chronic fluoxetine, we 
investigated the effects of fluoxetine in the NSF test and NIH test and found that chronic 




            Previous studies have demonstrated that activation of the cAMP cascade, 
including CREB, increases the proliferation and maturation of newborn neurons in adult 
mouse hippocampus (Fujioka et al., 2004). CREB is a transcription factor that is activated 
by its phosphorylation on Ser133 via cAMP-dependent protein kinase, as well as by Ca2+- 
and neurotrophic factor-dependent signaling pathways. cAMP-CREB cascade exerts a 
positive influence on neuronal cell proliferation in the hippocampus (Nakagawa et al., 
2002). In our study, increased neurogenesis is observed concurrently with reduced CREB 
or the active form of CREB (pCREB) expression, which implicates that CREB induction 
is not necessary for hippocampus neurogenesis. cAMP-CREB cascade is one of the key 
signal transduction pathways for regulation of cell proliferation and differentiation, 
however, other conditions such as Neurotrophic factors could directly regulate 
hippocampus neurogenesis. 
            Behavioral characterization of mice lacking 5-HT7 receptor has been inconclusive. 
Previous studies using light-dark box paradigm show no significant differences between 
5-HT7+/+ and 5-HT7−/− mice in C57BL/6J background in either the time spent in the 
light compartment or the number of transitions between the light and dark compartments 
(Roberts et al., 2004). Another strain of 5-HT7-/- mice in mixed129SvEV/C57BL/6J 
background was tested in elevated pluz mace and there was no difference in the time 
spent exploring the open arms or in the number of entries onto the open arms of the maze 
in both genotypes (Guscott et al., 2005). In our own experiments, we get mixed results. In 
novelty suppressed feeding test, we see increased latency to feed in 5-hrt7 -/- mice, which 
is indicative of increased anxiety level; in novelty induced hypophasia test, we observed 




/- mice, which indicates reduced anxiety level. One thing that needs to be noted is that 
novelty suppressed feeding test requires food deprivation 24 hours before testing, thus we 
cannot exclude the possibility that the experiment results could be confounded by hunger 
level, motivational conditions et al. 5-ht7 receptor blockade by antagonist has shown 
consistent result: antagonist induce anxiolytic effect in rats and mice (Wesolowska et al., 
2006a; Wesolowska et al., 2006b). Multiple conditions might explain such discrepancies: 
life-long genetic blockade might produce more dramatic and persistent changes, or 
develop some compensatory mechanisms to cope with the ablation in comparison to 
acute antagonist treatment; the genetic background might influence the behavior readout. 
Taken together, this shows the complex picture of 5-HT7 receptor in mediating anxiety-
related behaviors.  
            Our experiment results showed that 5-ht7 receptor is not required for chronic 
fluoxetine induced hippocampus neurogenesis and anxiolytic/antidepressant behavioral 
response. It is possible that other receptors might mediate this response. For example, 5-
HT1A receptors are generally thought to be involved in modulating both anxiety and 
depression-related behavior. It is shown that a 5-HT1A autoreceptor levels in adulthood, 
prior to antidepressant treatment, has close relevance to the responsiveness to fluoxetine 
(Richardson-Jones et al.). It is possible that 5-HT1A autoreceptor might mediate this 
chronic fluoxetine behavioral response. The fact that 5-HT7 receptor is not necessary for 
the effect of adult chronic FLX treatment on anxiety-and depression-like behaviors might 
point to that 5-ht7 receptor might play more important roles in other aspects like learning 
and memory.  
